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ABSTRACT 
 
 Transmissible spongiform encephalopathies constitute a group of mammalian 
neurodegenerative protein misfolding disorders, characterized by neuronal loss and gliosis in 
response to accumulation of an abnormal conformer (PrPsc) of the native cellular prion protein 
(PrPc).   The nature of the local inflammatory response and the potential contributions of 
microgliosis and astrocytosis to the progression of neuropathology have not been fully resolved.  
Shifts in microglial and astrocytic immunophenotypes have been demonstrated in other human 
neurodegenerative protein misfolding diseases. Similarly, we anticipated a fluid glial activation 
profile, characterized by transitions in phenotype markers and immunoproteasome induction, over 
the course of prion infection.  This dissertation sought to characterize the neuroinflammatory 
response to prion infection using a murine intracranial infection model.   
 Successive chromogenic immunolabeling and in-situ hybridization were employed in 
analyzing expression patterns of glial activation markers and a proteasomal subtype (PSMB10) 
over the timecourse of infection in a murine scrapie model.  Our model successfully recapitulated 
classical patterns of TSE-associated neuropathology and demonstrated a precocious microglial 
response, relative to other studies.  We also identified an upregulation of the proinflammatory 
enzyme iNOS in glial populations at late stages of disease incubation.  Colocalization analysis of 
glial cytoplasmic and activation markers allowed us to resolve an astrocyte-associated increase in 
Arg1 expression in clinical disease, despite lack of significant changes in global Arg1 expression.  
Although quantification of immunoproteasome subunit PSMB10 expression failed to yield 
significant temporospatial trends, this analysis characterized baseline expression patterns across 
16 brain regions.  Combined, these findings constitute a comprehensive in-situ evaluation of glial 
activation and present techniques novel to prion research.  
 
 
CHAPTER 1. LITERATURE REVIEW 
Background 
Transmissible spongiform encephalopathies 
Transmissible spongiform encephalopathies (TSEs) constitute a group of insidious 
neurodegenerative diseases that afflict a range of mammalian species, including humans (Kuru, 
Creutzfeldt-Jacob, Gerstmann-Sträussler-Scheinker), bovines (bovine spongiform 
encephalopathy), small ruminants (scrapie), and cervids (chronic wasting disease, CWD).  Prion 
diseases share a common pathology of prolonged incubation spanning months to decades, gradual 
loss of cognitive capacity, ataxia, emaciation and an invariably fatal outcome (Asher et al., 1976).  
The delayed symptomology of TSEs provides opportunities for unwitting dissemination of human 
infection through both vertical transmission of genetic variants (Webb et al., 2009; Owen et al., 
2014; Schmitz et al., 2016), and horizontal spread of acquired disease phenotypes via routine 
medical procedures (Sushma et al., 2016; Bonda et al., 2016; Rudge et al., 2015; Davanipour et 
al., 2014; Bradford et al., 2014; Gnanajothy et al., 2013; Thomas et al., 2013; Urwin et al., 2016; 
H. L. Kim et al., 2011; Hall et al., 2014). Additionally, the environmental persistence of the prion 
protein (Gough et al., 2010; Marin-Moreno et al., 2016; Nagaoka et al., 2010), increased 
prevalence of CWD (Zabel et al., 2017), cases of sporadic atypical BSE (Sala et al., 2012; 
Seuberlich et al., 2010; Ono et al., 2011; Saunders et al., 2012), and potential underestimation of 
actual food-borne infection rate (Oraby et al., 2016; Al-Zoughool et al., 2016) maintain animal-
derived prion agents as a credible zoonotic threat.    
TSE’s are not completely unique in their proteinaceous etiology, as there are increasing 
parallels between prion infections and a subset of chronic human neurodegenerative diseases.  
Even prior to the establishment of scientific consensus on the basic mechanism of prion 
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propagation,  researchers remarked on a degree of clinical homology between human TSEs and 
Alzheimer’s disease  (P. Brown et al., 1982).  Modern understanding of neurodegenerative 
pathology substantiates this recognition with the demonstration of prion-like ‘propagons’ of fibrils 
in Alzheimer’s (AD), Parkinson’s (PD), Huntington’s (HD) diseases and amyotrophic lateral 
sclerosis (ALS) composed of amyloid beta (Aβ) and tau, α-synuclein, and huntingtin, respectively.  
As reviewed by Aguzzi and Erana (Aguzzi et al., 2016; Erana et al., 2016), these entities share an 
amyloidogenic pathophysiology, wherein soluble oligomers of misfolded proteins can form self-
propagating fibrils and result in aggregate deposition within neurons and the neuropil.  However, 
infectivity of these subunits has yet to be demonstrated between individuals.  In light of this 
distinction, the term ‘prionoid’ was proposed by the authors to designate protein misfolding 
diseases where transmissibility has not been proven.  Evaluation of potential mechanistic 
homology between ‘prionoids’ and TSEs may provide valuable insight into their pathogeneses and 
suggest avenues for treatment.   
The contribution of glial activation to the progression of prion infection is controversial, 
with evidence for mediation of both protective and deleterious outcomes.  Incomplete 
understanding of early disease mechanisms contributes to lack of effective early diagnostics and 
treatment options for these diseases.  This review will seek to summarize current understanding of 
glial kinetics, immunophenotypes, and their effect on proteolysis and disease progression.   
 
Cellular prion protein (PrPc) 
In spite of clinical recognition of TSEs spanning 200 years (Liberski, 2012), the causative 
agent remained a mystery until the late 20th century.  The ‘protein only’ theory, first advanced in 
the 1980’s (Prusiner, 1982), proposed that TSE’s are caused by a proteinase K-resistant  
3 
 
proteinaceous infectious particle.  Pursuit of this unprecedented model of infectivity has yielded a 
mechanism of neurotoxicity mediated by self-propagating corruption of a native cytoplasmic prion 
protein, PrPc by a foreign peptide with an identical primary amino acid sequence (Hope et al., 
1986; Stahl et al., 1993; Pan et al., 1993).  Cellular prion protein is ubiquitously expressed on 
tissue membranes as a glycosylphosphatidylinositol (GPI)-linked glycoprotein with a 
predominance of alpha-helices in its secondary structure.  The highest concentration of PrPc is 
found in neural tissues, with increased expression in the hippocampus and thalamolimbic system 
(Benvegnu et al., 2010). 
Proposed functions of PrPc are varied and include cellular differentiation, neuronal 
excitability and metal homeostasis (Castle et al., 2017).  Despite conserved expression of the 
protein across mammalian species, PrPc does not appear necessary for survival.  Murine PrPc 
knock-out models display minimal phenotypic disturbance but are resistant to prion infection 
(Bueler et al., 1992; Bueler et al., 1993).  A line of Norwegian dairy goats, the only known mammal 
naturally deficient in PrPc, are also phenotypically normal, but display upregulation of 
proinflammatory genes (Malachin et al., 2017).  As discussed below, exposure of PrPc molecules 
to an aberrant PrPsc with a high beta-sheet composition catalyzes misfolding of native proteins, 
accumulation of PrPsc plaques and induction of neuronal degeneration by hitherto uncertain 
mechanisms.  
 
Prion types and strains  
Prion disease models can be subclassified by prion type and strain.  Prion types are grouped 
according to structural features that can influence the physical properties of the agent identified in 
the original host, whereas prion strains are separated by the pathophysiologic profile of infection 
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in a new host (Wemheuer et al., 2017).  For example, the Rocky Mountain Laboratories (RML) 
mouse-adapted strain of scrapie was obtained when ovine scrapie agent was inoculated into goats, 
resulting in a ‘drowsy’ phenotype, followed by serial passage in in mice (Striebel et al., 2011).  
Generation of new prion strains can be somewhat limited by the concept of a species transmission 
barrier, wherein infectivity of a strain within members of the same species is higher than between 
members of different species.  Depending on factors such as inoculation route and host PrPc 
conformation, interspecies infections may exhibit prolonged incubation times or fail to reproduce 
disease entirely (Greenlee et al., 2015).  For example, despite the ready oral transmissibility of 
scrapie between sheep and CWD between cervids, passage of these agents to cattle is only 
successful if instilled intracranially, and no cases of human infection of either has been recorded, 
despite inevitable unwitting consumption of infected animals (Greenlee et al., 2015).  However, 
Czub et al recently presented preliminary findings  of an ongoing oral CWD trial in Cynomolgus 
macaques, which suggested transmission of clinical disease to non-human primates following 
consumption of muscle from subclinically infected cervids (Stefanie Czub, 2017).   
Prohibitively long TSE incubation times required to study disease phenotypes in large 
mammals have driven the development of a vast variety of murine models capable of recapitulating 
infection patterns of different strains (Brandner et al., 2017).  Murine models offer a homogenous 
genetic background with shortened disease timecourse, and genetic manipulation can reproduce 
species-specific disease patterns as well as permit evaluation of the effects of PrP conformation 
and  PRNP polymorphisms on disease progression (Brandner et al., 2017).  Murine models of 
scrapie infection have been extensively employed in exploring prion pathophysiology and have 
contributed to foundational understanding of TSE infection, including strain-specific patterns of 
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neurodegeneration (Fraser et al., 1973; Bruce et al., 1991) and neuroinflammatory reactions (Giese 
et al., 1998; Carroll et al., 2016; Vincenti et al., 2015). 
 
Prion infection and pathogenesis 
PrPsc ingested in natural and experimental infection appear to enter Peyer’s patches in the 
alimentary tract and undergo amplification in dendritic cells, which subsequently transfer PrPsc to 
autonomic nerves in a proximity-dependent manner (Kujala, 2011; Prinz et al., 2003).  Tissue 
distribution of the prion agent varies by species.  Lymphotropic TSEs, such as CWD, scrapie and 
vCJD, accumulate broadly through lymphoid organs prior to detection in the CNS (Ersdal et al., 
2003; Sigurdson et al., 1999; D. A. Hilton et al., 1998).  In contrast, BSE appears to be directly 
neuroinvasive, forgoing initial peripheral amplification (Balkema-Buschmann et al., 2011).  
Mechanisms of intercellular PrPsc transmission are not fully elucidated.  As reviewed by Aguzzi 
(Aguzzi et al., 2016), proposed means of dissemination include exosomal transmission (Yim et al., 
2015), shedding into the ECM following cleavage by ADAM proteases (Altmeppen et al., 2015), 
tunneling nanotubules (Gousset et al., 2009), and endocytosis (Goold et al., 2013).  
Prion proteins exist in a variety of conformations and polymerization states that propagate 
under a model of recruitment and fragmentation (Collinge, 2016). Briefly, misfolded PrPsc 
particles stimulate and stabilize a conformational shift in PrPc, initiating a polymerization chain to 
form insoluble amyloidogenic fibrils (Collinge, 2016).  These fibrils can undergo sporadic 
fragmentation into a mix of oligomeric species that subsequently seed further PrPc conversion 
(Collinge, 2016).  The physical properties and biologic activity of these species vary.  While 
fibrillar aggregates are deemed biologically inert, it is hypothesized that infectivity and 
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neurotoxicity are mediated by oligomeric fragmentation species that, unlike fibrillar amyloid 
plaques, are soluble and partially PK sensitive (C. Kim, 2011; Mays et al., 2015).   
The observation that TSEs undergo prolonged subclinical incubation, despite rapidly rising 
post-inoculation prion titers in experimental infections (Hill et al., 2000), prompted the evolution 
of the two-phase hypothesis of infection kinetics.  Prion infections are characterized by an initial 
stage of rapidly propagating infectious moieties up to an infectivity plateau (Sandberg et al., 2011).  
This autocatalytic phase is clinically unremarkable.  Upon reaching the infectivity plateau, a new 
toxic PrPsc isoform characterized by PK sensitivity begins to proliferate until a toxic threshold is 
reached, manifesting as onset of rapidly progressive clinical disease (Sandberg et al., 2011).  The 
rate of propagation for this toxic species is directly proportional to the level of cellular PrP 
expression, while the autocatalytic phase appears PrPc-independent (Sandberg et al., 2011). Thus, 
transgenic mice with increased PrPc density achieve infectivity plateau at a similar rate to wild 
type mice, but attain toxic threshold and exhibit disease more rapidly thereafter (Sandberg et al., 
2011).  The mechanism of toxic conversion is unknown. This model dissociates neuroinfectivity, 
which peaks in subclinical stages, from the symptoms and lesions of neurotoxicity that have been 
used to characterize prion strains in infection models (Sandberg et al., 2014).  
 
Lesions 
Despite species-dependent spatiotemporal variability in lesion expression, deposition of 
PrPsc, neural vacuolation (“spongiform change”) and gliosis are universally manifested in hosts 
succumbing to prion diseases (Bruce et al., 1991; Carroll et al., 2016; Fraser et al., 1968; Legname 
et al., 2005; Hainfellner et al., 1997; Spraker et al., 2004; Wood et al., 1997).  Surprisingly, the 
pathoetiology of spongiform change histologically observed in terminal TSE brains remains 
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somewhat enigmatic.  Electron microscopy studies performed by Liberski et al (2005) revealed 
the membrane-bound contents of fatal familial insomnia and CJD vacuoles to consist of curled 
membrane fragments and amorphous “fluff” (Liberski et al., 2005).  Appearance of these 
predominantly intra-dendritic cavities was hypothesized to be a function of disrupted axonal 
transport (A. E. Williams et al., 1994) or lysosomal dysregulation (Betmouni et al., 1996).  
However, the variability of vacuole appearance relative to preservation technique prompted 
Betmouni et al to call this change “an informative artifact” (Betmouni et al., 1999).  Despite 
incomplete characterization of the vacuolar change, its appearance correlates to the toxic phase of 
infection (Sandberg et al., 2014) and the specific distribution pattern is useful in differentiating 
prion strains (Fraser et al., 1973).  
The eventual onset of neurologic symptoms in the clinical phase of prion infection occurs 
secondary to neuronotoxicity, manifesting histologically as regionally exacerbated synaptic loss 
and neuronal depletion (Cunningham et al., 2005; Reis et al., 2015; K. J. Hilton et al., 2013). 
Whether prion toxicity is exerted directly or through a secondary mechanism has not been fully 
elucidated.  There is some limited evidence that PrPsc can directly mediate neuron damage.  NMDA 
receptor-mediated excitotoxity was documented in a mouse model of CJD infection, though the 
mechanism remains uncertain (Ratte et al., 2008).  Several studies have additionally shown that 
PrPsc conformers can induce neuronal pore formation, resulting in abnormal membrane ion fluxes 
(Kourie et al., 2000; Berest et al., 2003; Solomon et al., 2010).  However, these effects appear to 
make a minor contribution to disease progression.  Secondary neurotoxicity due to accumulation 
of misfolded proteins and activation of the unfolded protein response (UPR) are discussed later in 
this review.   
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Activation of glial cells in response to prion infection is a well-documented phenomenon 
(A. Williams et al., 1997).  Microglia and astrocytes have been demonstrated to undergo reactive 
hypertrophy during the proposed autocatalytic phase, well in advance of clinical disease (Diedrich 
et al., 1991; Sandberg et al., 2014; Carroll et al., 2016).  Marked increases in microglial numbers, 
most pronounced in the hippocampus and thalamus, are driven by local expansion of resident cells, 
rather than recruitment of circulating monocytes (Gomez-Nicola et al., 2013).  Glial activation in 
the course of prion infection can produce a hostile pro-inflammatory environment that may 
contribute to degenerative change.  As reviewed in greater depth below, astrocytes and microglia 
are known to secrete inflammatory cytokines and reactive oxygen species (Tribouillard-Tanvier et 
al., 2009; Tribouillard-Tanvier et al., 2012; Sorce et al., 2014).  These environmental changes may 
exacerbate cellular oxidative stress incurred through loss of PrPc’s antioxidant function (Keshet et 
al., 1999; Choi et al., 1998; Guentchev et al., 2000).  
 
Microglia in Prion Disease 
Histology of microglia 
Several decades after Metchnikoff’s observations of tissue-specific phagocytes at the end 
of the 19th century (Gordon, 2008), Pío del Río-Hortega confirmed microglia as unique neural 
resident phagocytes (Tremblay et al., 2015).  Microglial ontogeny has since been disputed 
alongside that of other members of the mononuclear phagocytic system. More recently, the theory 
of bone marrow derivation has been challenged by fate-mapping experiments that traced 
microglial origins to erythromyeloid progenitors in the yolk sac (Sheng et al., 2015; Ginhoux et 
al., 2016).  Immunohistologic differentiation of microglia from bone marrow derived macrophages 
has been complicated by common antigen expression, including F4/80, CD68, CX3CR1, CD11b 
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and Iba1 (Ginhoux et al., 2015).  More recently, TMEM119, a transmembrane protein of uncertain 
function, has been demonstrated to specifically label microglia, with no myeloid cross-reactivity 
(Satoh et al., 2016).   
Murine microglial precursors undergo multiphasic colonization of the cortex and retina 
after embryonic day 10, with waves of invasion radiating from pial and ventricular linings 
(Swinnen et al., 2013).  Population densities are unevenly distributed throughout the brain.  In the 
adult murine brain, microglia concentrate in the gray matter, with the highest densities observed 
in the basal ganglia, substantia nigra, hippocampal dentate gyrus and olfactory tubercle, followed 
by the diencephalon (Lawson et al., 1990).  The lowest numbers are observed in the 
rhombencephalon (Lawson et al., 1990).  In contrast, human microglia preferentially populate 
telencephalic white matter and appear to be most numerous in the brainstem (Mittelbronn et al., 
2001).   
 
Microglia in the healthy brain 
Microglia are dynamic cells that can shift along a spectrum of activation states.  
Morphologically, these cells exist on a continuum ranging from a ‘resting’ form, characterized by 
a small soma and thin ramified processes, to a round-bodied ‘active’ cell with thick processes, to 
a de-ramified phagocyte (Walker et al., 2014).  A similar fluidity is observed functionally, with 
experimentally inducible extreme polarization states.  In an adaptation of peripheral blood 
monocyte terminology, microglia can be characterized as inactive “surveillant” (Wake et al., 
2009), or belonging to one of 2 main activation phenotypes: “classically activated” pro-
inflammatory (M1), or “alternatively activated” anti-inflammatory (M2), with several functional 
subtypes described (Edwards et al., 2006).  
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In the developing brain, migrating amoeboid microglia (Swinnen et al., 2013) have been 
demonstrated to regulate neurogenesis via phagocytosis of neural precursors and driving of 
synaptic pruning (Cunningham, 2013; Zhan et al., 2014).  Maturation, characterized by 
arborization of thin highly motile processes, produces a ‘surveillant’ phenotype that continuously 
monitors neuronal synapses (Nimmerjahn et al., 2005) and phagocytically modulates neurogenesis 
in the healthy adult brain (Sierra et al., 2014).   
As demonstrated by Butovsky et al., development and maintenance of these quiescent cells 
is driven extensively by microglial response to TGFβ1 signaling (Butovsky et al., 2014).  TGFβ1 
secreted by neurons and astrocytes upregulates expression of the fractalkine receptor (CX3CR1) 
on microglia (Abutbul et al., 2012), which in turn interacts with its neuronal ligand to modify 
synaptic circuitry (Paolicelli et al., 2011).  Loss of TGFβ1 in knockout studies resulted in decreased 
CX3CR1 expression (Abutbul et al., 2012), induced microgliosis and neurodegeneration (Brionne 
et al., 2003).   
In addition to non-homogenous spatial density, microglial populations in the healthy brain 
appear to have regionally specialized morphology and physiology.  Transcriptomic analysis 
performed by Grabert et al suggests that cerebellar and hippocampal microglia are more 
immunologically “alert” with increased expression of genes involved in antigen processing and 
pathogen killing (Grabert et al., 2016).  These findings of functional niches are supported by 
Stowell et al’s report of phenotypic differences between cerebellar and cortical microglia in vivo 
(Stowell et al., 2017).  Cerebellar microglia were characterized by decreased density, relative de-
ramification reminiscent of activated phenotypes, and increased somal mobility (Stowell et al., 
2017).  Similarly amoeboid subtypes have been reported as the primary resident microglial 
morphology in the circumventricular organs of healthy murine brains, a structure exposed to 
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circulating molecules due to lack of a blood-brain barrier (Takagi et al., 2017). These cells 
displayed increased activation markers, suggesting localized immunologic priming.   Furthermore, 
phenotypic variation has been demonstrated on a substructural level.  Work by De Baise et al 
showed marked variation in microglial morphology and density between well-demarcated regions 
of the basal ganglia (De Biase et al., 2017).  Morphologic dimorphism was accompanied by 
significant localized variation in lysosomal content, membrane polarization, and levels of cellular 
metabolism-associated transcripts (De Biase et al., 2017).  Findings of regional phenotypic 
variation carry implications toward structurally differentiated disease susceptibility.  
 
Microglial response to injury 
Neural insult, whether mechanical, infectious or senile, can induce microglia to undergo a 
hypertrophic change of somatic enlargement, thickening and retraction of cellular processes to 
assume an ‘amoeboid’ phagocytic morphology.  Histologically characterized as ‘active”, these 
cells can be functionally polarized under experimental settings to produce reactive phenotypes 
similar to that of peripheral monocytes (Colton, 2009). As reviewed by Orihuela et al,  IFNγ is 
understood to induce ‘classical’ inflammatory functions such as production of IL1β, IL6, TNFα, 
and NO (Orihuela et al., 2016).  This phenotype is referred to as M1 microglia.  Resolution of the 
inflammatory milieu and elaboration of IL4, IL13 by peripheral cells can change microglial 
profiles to an anti-inflammatory (M2) state that stimulates tissue repair (Orihuela et al., 2016).  
Similarly, exposure to IL10, TGFβ or apoptotic bodies promotes a subtly different 
immunosuppressive phenotype termed ‘acquired deactivated’ (Orihuela et al., 2016).  These 
profiles are not fixed.  Individual cells respond to local microclimates with dynamic transition 
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between states, whose balance may influence tissue pathology in a temporospatially dependent 
manner.    
Although purely polarized populations are unlikely to exist in vivo and antigen expression 
can be mixed even on individual cells, histologic differentiation of M1 and M2 microglia can be 
attempted using prescribed functional marker subsets.  M1 microglia express elevated CD86, 
iNOS, IFNy, TNFa and IL1b (Kobayashi et al., 2013; Colton, 2009).  M2 polarization induces 
Arg1, Ym1, FIZZ1 and CD206 expression (Colton, 2009).  Two canonical markers, iNOS and 
Arg1, competitively inhibit each other through mutual reliance on arginine metabolism (Rath et 
al., 2014).  
The role of activated microglia in neurodegenerative diseases is complex, with evidence 
for mediation of both neuroprotective and neurotoxic effects.  As reviewed by Harry et al and 
Sierra et al microglial activation can create a hostile environment through elaboration of reactive 
oxygen species and inflammatory cytokines, as well as through inappropriate phagoptosis of viable 
neurons (Harry et al., 2008; Sierra et al., 2014).  However, they can also promote neurogenesis 
(Thored et al., 2009; De Lucia et al., 2016) and limit neurotoxic inhibitory signaling through 
synaptic stripping (Z. Chen et al., 2014).  
 
Microgliosis in prion infection.  
In prion-infected brains, microglial activation occurs well in advance of clinical disease, 
and is characterized by marked cellular hypertrophy and hyperplasia (Sandberg et al., 2014; Carroll 
et al., 2016; Gomez-Nicola et al., 2013; Giese et al., 1998).  However, studies of tissue 
inflammatory signatures and microglial polarization in prion disease have yielded contradictory 
results.   
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In 2002, Cunningham et al. reported that a paradoxical lack of proinflammatory cytokine 
production in morphologically activated microglia in intracranial ME7 prion infection was 
governed by a high concentration of anti-inflammatory TGFβ1 in the extracellular matrix 
(Cunningham et al., 2002).  Maintenance of this ‘alternatively activated’ M2 profile model was 
later supported by several other investigators (Perry et al., 2002; Boche et al., 2006; Hughes et al., 
2010).  It was proposed that these anti-inflammatory microglial profiles may promote synaptic 
dissolution in early prion infection, however synaptic loss was shown to occur independently of 
microglial involvement (Šišková et al., 2009).  These results are in contrast to more recent studies 
evaluating transcriptomics and cytokine expression, which suggest a proinflammatory neurotoxic 
microglial profile, with elevation of a wide variety of inflammatory mediators, including IL1β, 
IL6, TNFα, IFNγ, caspase 4, TIMP1 and matrix metalloprotease 12 (Vincenti et al., 2016; Carroll 
et al., 2016; Tribouillard-Tanvier et al., 2009; Newsom et al., 2011; Moody et al., 2011; Song et 
al., 2012).  Furthermore, microglial elaboration of reactive oxygen species, NO and oxygen bursts 
in even early preclinical stages has been demonstrated to induce lipid peroxidation and oxidative 
stress in surrounding tissues (Sorce et al., 2014; Hafner-Bratkovic et al., 2012; Yun et al., 2006). 
These discrepancies are likely attributable, at least in part, to strain/host/inoculation variation 
between these studies.  Additionally, sampling technique may have been a contributing factor, as 
authors used homogenates of whole or partially dissected brains to analyze mRNA transcript and 
cytokine levels.  Given the localized nature of prion lesions and glial distribution, subtle 
differences in cytokine microclimates would have been lost to signal dilution in these studies.   
Studies evaluating the effects of microglial ablation on disease phenotype yielded divergent 
outcomes, depending on the method of microglial inactivation.  Arrest of microglial proliferation 
by blockage of mitogenic signaling through CSF1 receptors resulted in decreased 
14 
 
neurodegeneration and prolonged survival in ME7-infected mice (Gomez-Nicola et al., 2013).  
However, a recent study repeating CSF1R inhibition with ME7 and 22L prion strains resulted in 
marked acceleration of neuropathology (Carroll et al., 2018).  Similarly, when microglia were 
pharmacologically depleted from RML-infected cerebellar organotypic cultured slices, there was 
a marked increase in neuronal death (Zhu et al., 2016).  Microglia also appear to modulate 
neurogenesis and slow disease progression through removal of apoptotic bodies (De Lucia et al., 
2016; Kranich et al., 2010).  In summary, reported microglial inflammatory phenotypes vary 
between studies and their effects on disease progression appear mixed.   
 
Astrocytes 
Histology of astrocytes 
Astrocytes are a morphologically diverse neuroglial population arising from radial glial 
progenitors (Doetsch, 2003).  As the most numerous neural cell type, they are highly represented 
in all brain regions, but appear to be most dense in the hippocampus, hypothalamus, corpus 
callosum and cerebellar white matter of the rodent brain (Savchenko et al., 2000).  Initial 
morphology studies divided astrocytes into fibrous and protoplasmic subtypes, characterized by 
long thickened processes for the former and highly branched thin processes for the latter 
(Andriezen, 1893; Miller et al., 1984).  Fibrous astrocytes concentrate in white matter tracts, while 
protoplasmic astrocytes are diffusely distributed through gray matter (Andriezen, 1893).  Beyond 
this basic distinction, functional differentiation of astrocytes in the healthy brain is suggested by 
marked variability in physiologic parameters, including receptor expression (Cai et al., 2000; Höft 
et al., 2014; Reuss et al., 2000), electrophysiological profiles (McKhann et al., 1997; Hibino et al., 
2004), proliferative capacity (Kriegstein et al., 2009), and gene expression (Yeh et al., 2009).  
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Astrocytic heterogeneity extends to surface marker expression, confounding 
comprehensive histologic identification of astroglial populations (Kimelberg, 2004; Ogata et al., 
2002).  For example, glial fibrillary acidic protein (GFAP), a canonical astrocytic marker, is 
expressed preferentially by fibrous astrocytes in white matter of healthy brains, with limited 
presence in protoplasmic gray matter astrocytes (Walz et al., 1998; Cahoy et al., 2008). 
Furthermore, immunohistochemical labeling for GFAP is confined largely to wide perisomal 
processes, representing only 15% of the total cell volume (Bushong et al., 2002).  Similar regional 
immunoreactivity is observed with glutamate transporter markers (Macnab et al., 2007; Lehre et 
al., 1995).  In contrast, aldehyde dehydrogenase 1 family, member L1 (Aldh1L1), an alternative 
astrocyte marker, labels fine astrocytic processes via IHC and is panastrocytic in transcriptomic 
expression (Cahoy et al., 2008).  Markers specific for reactive astrocytes include the acute phase 
protein Lcn2 and Serpina2n, a proteinase inhibitor (Zamanian et al., 2012).  
 
Astrocytes in the healthy brain 
Astrocytes display a vast variety of homeostatic functions in the healthy brain, including 
guidance of neurite outgrowth (Powell et al., 1999), synaptogenesis (Ullian et al., 2001), glycogen 
metabolism (A. M. Brown et al., 2007), osmotic regulation (Simard et al., 2006) and maintenance 
of the blood-brain barrier (Abbott et al., 2006). Additionally, astrocytes recycle excess glutamate 
to limit its excitotoxic effects (Rothstein et al., 1996).  Astrocytic signaling appears to involve both 
gap junctions (Giaume et al., 2010) and fluctuations in Ca2+ levels (Khakh et al., 2015), permitting 
rapid intercellular communication in the absence of action potentials.  Disruption of astrocytic 
signaling networks and homeostatic functions in response to neuroinflammation can contribute to 
neurotoxicity (Giaume et al., 2010; Liddelow et al., 2017).  
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Astrocytic response to injury 
Astrogliosis can be initiated by a large variety of peripherally and locally generated 
molecular stimuli elaborated in response to either neural or systemic disease (Sofroniew, 2015). 
Activated astrocytes undergo hypertrophy of their cellular processes, which corresponds to 
upregulation of cytoskeletal intermediate filaments, especially glial fibrillary acidic protein 
(GFAP) and vimentin (Wilhelmsson et al., 2004).  Higher grades of neural insult can induce 
astrocytic proliferation and formation of a glial scar (Wanner et al., 2013; Bardehle et al., 2013). 
Activated astrocytes can secrete many classes of effector molecules, including growth factors, 
extracellular matrix modulators, neurotransmitters and cytokines, such as IL6, IL1β, TNFα, IFNγ, 
TGFβ (Sofroniew, 2015).  Similar to microglia, different activation stimuli can result in formation 
of multiple phenotypes of astrocytes (Anderson et al., 2014).  Transcriptomic analysis performed 
by Zamanian et al (2012) demonstrated marked differences in gene expression between ischemia 
and LPS-activated astrocytes.  Ischemic damage seemed to induce astrocyte secretion of 
neurotrophic factors and repair-mediating cytokines, whereas LPS promoted expression of 
synaptolytic complement components (Zamanian et al., 2012). These proinflammatory astrocytes, 
termed A1, can be activated by IL1α, TNFα and C1q generated by “classically-activated” 
microglia (Liddelow et al., 2017).  Unlike ‘protective’ A2 phenotypes, these cells appear to 
promote caspase-mediated neuronotoxicity and fail to perform homeostatic functions, such as 
phagocytosis and synaptic maintenance (Liddelow et al., 2017).  
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Astrocytosis in prion infection 
 
Astrocytosis is one of the earliest changes associated with prion infection, with 
upregulation of intermediate filament transcripts as early as 40 days post inoculation and strain-
dependent spatial correlation to PrPsc deposition (Carroll et al., 2016).  GFAP expression has even 
been proposed as a diagnostic infectivity bioassay when coupled to bioluminescent reporters in 
transgenic mice (Tamgüney et al., 2009). Timing of astrogliosis onset varies by strain, however, it 
appears to uniformly precede microgliosis, vacuolation and clinical symptoms (Carroll et al., 
2016).   
Astrocytes are the earliest accumulators of PrPsc and appear to transmit infectious prions 
directly to neurons (Diedrich et al., 1991; Victoria et al., 2016; Sarasa et al., 2012; Krejciova et 
al., 2017).  In fact, neuronal pathology could be induced in transgenic mice expressing PrPc 
exclusively on astrocytes and in co-cultures of astrocytes with Prnp0/0 neurons (D. R. Brown, 
1999; Jeffrey et al., 2004), suggesting a critical role for astrocytes in generation of toxic PrPsc 
species.   
During prion infection, astrocytes secrete inflammatory cytokines, such as IL1β, IL6, IL12 
and TNFα, as well as a variety of chemokines (Tribouillard-Tanvier et al., 2009; Song et al., 2012).  
Astrocytes appear to promote microglial recruitment during preclinical stages of prion disease 
through elaboration of chemokines CCL4 and CCL5 (Marella et al., 2004). Furthermore, 
astrocytes display a ‘priming’ mechanism similar to microglia, whereupon glia activated by a 
‘sterile’ prion infection secrete exaggerated levels of chemokines in response to subsequent 
inflammatory cytokine stimulation (Hennessy et al., 2015).  Partial inhibition of astrocytic 
activation in an IL1RI knock-out mouse lead to a decrease in PrPsc accumulation and extended 
survival times (Schultz et al., 2004).  
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In summary, astrogliosis is an early feature of prion infection that appears to promote PrPsc 
propagation and may mediate neuropathology, either through loss of homeostatic function or 
exacerbation of neuroinflammation.  
 
The Ubiquitin Proteasome System (UPS) and Immunoproteasomes in Prion Disease 
 
Proteolytic inhibition as a mechanism of neurotoxicity 
Prion-mediated neurotoxicity may occur secondary to accumulation of misfolded proteins 
and initiation of the unfolded protein response (UPR).  Prion infection has been documented to 
trigger dysfunction of both major branches of cellular proteolysis – autophagy and the ubiquitin 
protease system.  Autophagocytic activation and dysfunction have been documented in multiple 
infection models (Boellaard et al., 1991; Liberski, 2012; Xu et al., 2012), and PrPsc oligomers have 
been demonstrated to inhibit the 26S proteasome (McKinnon et al., 2016; Kristiansen et al., 2007). 
Subsequent buildup of misfolded proteins can trigger the unfolded protein response, which, if 
unresolved, can initiate caspase-mediated apoptosis.  Activation of UPR signaling mediators has 
been documented in prion infection models, and their selective inhibition appears to be 
neuroprotective (Moreno et al., 2012).   
 
The Ubiquitin Proteasome System (UPS) 
26S proteasome structure and function. The ubiquitin proteasome system (UPS) 
degrades up to 90% of the cell’s defunct peptides and contributes to rapidly terminating signaling 
cascades, modifying transcriptional activity of the cell, and replenishing the amino acid pool in 
times of starvation (Kristensen et al., 2008; Rock et al., 1994; Schubert et al., 2000; Lecker et al., 
2006).  Prion infection, itself a disorder of protein misfolding, adversely affects cellular proteolysis 
19 
 
and capacity for removal of abnormal proteinaceous aggresomes.  This last section will review the 
26S proteasome, it’s immunologically inducible subunits and their potential role in prion disease.  
The UPS is composed of two enzyme subsets – the ubiquitinating and the proteolytic.  
Malformed and damaged peptides are tagged for degradation by the ubiquitin system, which 
sequentially catalyzes the addition of ubiquitin to a peptide substrate, labeling the peptide for 
degradation (Lecker et al., 2006). 
The ubiquitinated peptides then enter the proteolytic half of the UPS pathway, mediated by 
the cytosolic 26S proteasome.  This superstructure is composed of two parts – a 19S cap and a 20S 
proteasome.  The barrel–shaped 20S proteasome is composed of 4 seven-membered rings:  2 rings 
of beta subunit rings sandwiched between a pair of alpha subunit rings (Lecker et al., 2006).  The 
nineteen proteins of the 19S regulatory cap are primarily responsible for granting ubiquitinated 
peptides access to enter the proteasome barrel for degradation (Lecker et al., 2006). 
Within the beta rings of the 20S barrel, three of the constitutively expressed beta subunits 
(β1, β2, β3) can cleave admitted peptides between specific patterns of amino acids, exhibiting 
activity akin to that of certain soluble proteases (caspase, trypsin, chymotrypsin, respectively) 
(Lecker et al., 2006).  Once all recognized cleavage sites are catabolized, the 3-25 amino acid-long 
peptide fragments are released into the cytosol to be further degraded by soluble peptidases and 
recycled (Lecker et al., 2006). 
 
The 26S proteasome and prion infection.  Inhibition of the 26S proteasome by prion 
infection has been demonstrated both in vitro (Kristiansen et al., 2007) and in vivo (McKinnon et 
al., 2016), with consequences including increased rates of neuronal degeneration and PrPsc 
deposition.  Experimental inhibition of the 26S proteasome results in similarly increased formation 
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of PrPsc aggresomes and exacerbated caspase-mediated neuronal apoptosis (Kristiansen et al., 
2005).  In these studies, neuronal toxicity and proteasomal impairment was associated with non-
fibrillar PrPsc aggregates, suggesting that this process is mediated by toxic oligomeric species 
(Kristiansen et al., 2007).  Inhibition of the 26S proteasome was reported to parallel PrPsc 
deposition, occurring well before onset of clinical disease, with initial aggregation of ubiquitinated 
proteins appearing in both neurons and astrocytes (McKinnon et al., 2016).  
 
Immunoproteasomes 
Immunoproteasome structure and function.  In the 1990’s, a structural analog of the 
classical 26S proteasome responsible for generating the majority of MHC I-peptides was 
characterized in antigen presenting cells (APCs), including microglia (Griffin et al., 1998).  This 
phenotype is capable of higher rates of peptide degradation, and its altered cleavage pattern grants 
breakdown products increased affinity for MHC class I presentation (Raule et al., 2014).   
It was discovered that assembly of this immunoproteasome phenotype could be induced in 
non-APCs under the influence of environmental conditions, such as inflammation, infection, 
hyperglycemia, oxidative and heat stress (Griffin et al., 1998; Hensley et al., 2010).  Most notably, 
exposure of cells to the inflammatory cytokines IFNα/β/γ and TNFα was shown to trigger a 
phenotypic transition from the constitutive 26S proteasome to the immunoproteasome (Bose et al., 
2001; Jakel et al., 2009; Gavilan et al., 2009).  
Under cytokine stimulation, expression of the catabolic beta subunits in non-antigen-
presenting-cells, and thus the proteolytic specificity of the 26S proteasome can be transcriptionally 
altered (Ferrington et al., 2012).  The constitutive proteolytic subunits of the 26S proteasome, β1, 
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β2 and β3, are replaced in the beta rings by β1i (LMP2, PSMB9), β2i (MECL1, PSMB10), β5i 
(LMP7, PSMB8), respectively (Ferrington et al., 2012).   
 
Immunoproteasome role in neurodegenerative diseases.  While tissue expression is 
highest in immune organs, such as lymph nodes and thymus, low levels of immunoproteasome 
subunits are present in healthy murine and human brains (Stohwasser et al., 1997; Piccinini et al., 
2003).  Microglial induction of immunoproteasome subunits has been demonstrated to occur in 
response to IFNγ stimulation, resulting in increased production of inflammatory mediators, such 
as TNFα and IL6 (Stohwasser et al., 2000). Similarly, immunoproteasomal inhibition resulted in 
decreased microglial capacity to respond to inflammatory stimuli, resulting in dampening of NFκb 
and iNOS induction, and production of IL1β, NO and TNFα (Moritz et al., 2017; X. Chen et al., 
2015).   
Immunoproteasomes may additionally play a role in determining the immunophenotype of 
macrophages.  A 2016 report by Chen et al found that functional inhibition of LMP2 (β1i, PSMB9), 
an immunoproteasome subunit, promoted M2 polarization in alveolar macrophages (S. Chen et 
al., 2016).  While immunoproteasomal upregulation was demonstrated in both polarization states, 
this occurred in a transcriptionally independent manner in M2 macrophages, demonstrating 
increased signal on western blots with no concurrent elevation of mRNA transcripts (S. Chen et 
al., 2016). 
Upregulation of immunoproteasome expression has been documented in ageing brains and 
in neurodegenerative diseases, including Alzheimer’s, Huntington’s and amyotrophic lateral 
sclerosis (Gavilan et al., 2009; Orre et al., 2013; Cheroni et al., 2009; Mishto et al., 2006; Diaz-
Hernandez et al., 2003).  The contribution of immunoproteasomes to these diseases is uncertain 
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and entity-specific.  When immunoproteasomes were inhibited in murine models of Alzheimer’s, 
traumatic brain injury and stroke, neuroinflammation was decreased (Orre et al., 2013; Wagner et 
al., 2017; X. Chen et al., 2015; Moritz et al., 2017).  Similar inhibition in an ALS model resulted 
in exacerbation of disease (Ahtoniemi et al., 2007).  
 
Immunoproteasomes in prion infection.  Cellular prion proteins have been demonstrated 
to act as substrates for immunoproteasomes in-vitro (Tenzer et al., 2004).  While pathogenic prions 
appear to impair constitutive proteasome function (Deriziotis et al., 2011; McKinnon et al., 2016), 
studies of immunoproteasome expression and impact on prion disease are limited.  Given 
indications of immunoproteasomal involvement in other ‘prionoid’ diseases and the increasing 
evidence of proinflammatory signaling and oxidative damage in prion infection, 
immunoproteasome activation could be anticipated.  However, a 2010 report by Amici et al. of 
scrapie infection in sheep demonstrated an overall increase of proteasomal activity in brainstems 
of infected animals, but did not observe a change in immunoblot immunoproteasome expression 
in brainstem homogenates (Amici et al., 2010).  This study compared only clinical and unaffected 
animals and was limited by sample location (brainstem only) and lack of in-situ evaluation of 
subunit expression, thus potentially losing data to signal dilution (Amici et al., 2010).   
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Abstract 
Mammalian transmissible spongiform encephalopathies (TSEs) induce marked activation 
of astrocytes and microglia that precedes neuronal loss and cognitive decline.  Investigation of 
clinical parallels between TSEs and other neurodegenerative protein misfolding diseases, such as 
Alzheimer’s, has revealed similar patterns of neuroinflammatory responses to accumulation of 
self-propagating amyloids.  The contribution of glial activation to the progression of protein 
misfolding diseases is controversial, with evidence for mediation of both protective and deleterious 
effects.  Glial populations exhibit a heterogeneous distribution throughout the brain, and are 
capable of dynamic transitions along a spectrum of functional activation states between pro- and 
anti-inflammatory polarization extremes.  Using a murine model of scrapie (RML), this study 
sought to characterize the neuroinflammatory response to prion infection by evaluating glial 
activation across 15 brain regions over time, and correlating it to traditional markers of prion 
neuropathology, including neuropil vacuolation and PrPsc deposition.  We used quantitative 
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immunohistochemistry to evaluate glial expression of iNOS and Arg1, markers of classical and 
alternative glial activation, respectively.  Our results indicate progressive upregulation of iNOS in 
microglia, consistent with a pro-inflammatory phenotype, and a mixed astrocytic profile featuring 
iNOS expression in white matter tracts and detection of Arg1-positive populations throughout the 
brain.  These data establish a comprehensive temporospatial lesion profile for this infection model, 
and contribute evidence of multiple glial activation states.  
 
Introduction 
 
Transmissible spongiform encephalopathies are an insidious, invariably fatal group of 
neurodegenerative diseases known to afflict a variety of mammalian species, including humans 
(Kuru, Creutzfeldt-Jacob, Gerstmann-Sträussler-Scheinker), bovines (bovine spongiform 
encephalopathy, BSE), small ruminants (scrapie), and cervids (chronic wasting disease, CWD).  
Although the exact mechanism of neurotoxicity is uncertain, infectivity and eventual 
neurodegeneration in prion infection is mediated by self-propagating corruption of a native 
cytoplasmic prion protein, PrPc, by a misfolded protein with an identical primary amino acid 
sequence, PrPsc. 56, 66  Misfolded PrPsc particles stimulate and stabilize a conformational shift in 
PrPc, initiating a polymerization chain to form insoluble amyloidogenic fibrils. 16  These fibrils can 
undergo sporadic fragmentation into a mix of oligomeric species that subsequently seed further 
PrPc  conversion. 16   Elements of this proteinaceous etiology are increasingly recognized in other 
classes of human neurodegenerative diseases,1, 22 such as Alzheimer’s (AD), 47, 75 Parkinson’s 
(PD),69 83 and Huntington’s (HD)43, 60 diseases and Amyotrophic Lateral Sclerosis (ALS).42 
Microglia, yolk-sac derived resident neural phagocytes,26 undergo activation and 
proliferation in response to misfolded oligomers in human neurodegenerative protein misfolding 
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diseases and classical prion disease alike. 25, 32, 47, 60, 83  The contribution of microgliosis to 
neuroinflammation is incompletely elucidated.  There is evidence for mediation of both deleterious 
effects, such as through generation of reactive oxygen species and inappropriate neuronal 
phagoptosis,8, 31 as well as neuroprotective mechanisms, including neurogenesis20 and synaptic 
stripping 13.  The study of neuroinflammation is further complicated by the apparent physiologic 
fluidity of microglial populations, which can undergo dynamic transition between activation states.  
Phenotypic polarity can be induced in cultured microglia resulting in manifestation of pro-
inflammatory “M1” or anti-inflammatory “M2” activation states characterized by divergent 
secretory and phagocytic profiles.55  M1-polarized microglia, which can be experimentally 
stimulated by IFNy to generate pro-inflammatory IL1β, IL6, TNFα and NO 17 have been reported 
in models of AD,50 PD,41, 83 and ALS 5.  However, there is evidence for spatial and temporal 
variation of microglial phenotypes during disease progression.  M2 microglia, which can be 
generated in-vitro in response to Th2 cytokines, appear to cluster around Aβ plaques in AD,35 and 
predominate in early pre-clinical stages of both AD and ALS, with a shift to M1-skewed 
phenotypes in late disease.29, 35   
Studies characterizing the inflammatory profiles of microglia in experimental prion 
infections have yielded contradictory results, with earlier evidence suggesting a paradoxical M2 
microglial profile despite an activated morphology,6, 18, 33, 77 while more recent transcriptomic and 
cytokine array analyses support a neurotoxic microglial profile and a pro-inflammatory cytokine 
milieu associated with M1 activation.10, 11, 27, 51, 53, 64, 71, 74  These discrepancies are likely 
attributable, at least in part, to strain, host, and collection time-point variation between these 
studies.  Additionally, sampling technique may have been a confounding factor, as authors used 
homogenates of whole or partially dissected brains to analyze mRNA transcript and cytokine 
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levels.  Microglial distribution is non-homogeneous throughout the brain, with marked variation 
in population density,40 transcriptomes,28 surface activation markers,67 and physiologic 
parameters19.  Microglial subsets are highly localized and can be resolved to a substructural level 
with sharp lines of border demarcation,19 suggesting that microglial response to neurodegenerative 
disease could vary markedly on a regional level.  
Astrocytosis is one of the earliest changes observed in prion infection,11 and astrocytes 
have been implicated in PrPsc accumulation and transmission to neurons.21, 39, 61, 72  Activated 
astrocytes can secrete either neuroprotective molecules or pro-inflammatory cytokines, depending 
on the inciting stimulus.4, 63, 82  An activation scheme similar to M1/M2 differentiation has been 
proposed for astrocytes, with “A1” phenotypes associated with neuronotoxicity and “A2” 
phenotypes with neuroprotection.45, 46  Experimental astrocytic polarization into “classical” and 
“alternative” activation patterns with differential expression of iNOS and Arg1 has been 
demonstrated in culture.34  Astrocyte subclasses have not been investigated in prion disease.  
The aim of this study was to characterize the glial response to prion infection using a mouse 
model of scrapie (RML) by evaluating glial activation over time and correlating it to classical 
markers of prion neuropathology, including neuropil vacuolation, and PrPsc deposition.  Although 
gliosis is a well-documented phenomenon in prion infection,11, 25, 59 this study represents a 
comprehensive time course investigation across 15 brain regions with in-situ expression analysis 
for iNOS and Arg1, canonical markers of glial polarization. 57, 68  We found that microgliosis late 
in the clinical time course is associated with pro-inflammatory upregulation of iNOS, and minimal 
Arg1 expression.  Colocalization analysis revealed predominantly astrocytic Arg1 expression in 
the cerebellum and medulla, with isolated iNOS-positive astrocyte populations in the cerebellar 
peduncles and internal capsule.  This was an unexpected finding indicating the possible existence 
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of multiple astrocytic inflammatory phenotypes. These data provide a detailed temporospatial 
characterization of neuropathology and gliosis in the RML scrapie infection model, contributing 
insight into glial activation dynamics and evidence for multiple activation states.  
 
Materials and Methods 
Animals and Tissue Preparation 
This experiment was performed in accordance with the Guide for the Care and Use of 
Laboratory Animals, and approved by the Institutional Animal Care and Use Committee at the 
National Animal Disease Center (protocol #3985). 
C57BL/6 mice aged 6 to 8 weeks from an inbred colony maintained at the USDA National 
Animal Disease Center were inoculated intracranially into the right cerebral hemisphere with 20 
µL of 10% w/v brain homogenate in PBS pooled from C57BL/6 mice terminally ill with the 
mouse-adapted Rocky Mountain Laboratories (RML) strain of the scrapie agent. Groups of mice 
were euthanized at predetermined time points of 30 (n=4), 60 (n=4), 90 (n=4), and 120 (n=5) days 
post inoculation (DPI), along with a group of animals that was allowed to survive until clinical 
signs necessitated euthanasia at 155 DPI (n=5). Age-matched C57BL/6 negative controls were 
inoculated with 10% w/v normal brain homogenate (NBH) in PBS and included at each time point 
(30, 90, 120 DPI n=2; 60 DPI n=4; 155 DPI n=2). Brains were collected into 10% neutral buffered 
formalin. After 24 hours of fixation, brains were transversely sectioned at four levels: mid-
cerebellum, rostral colliculus, thalamus and hypothalamus, and rostral cerebrum at level of septal 
nuclei. Tissues were processed by routine histologic methods, embedded in paraffin, sectioned at 
5 μm, and mounted on glass slides for hematoxylin and eosin staining or immunohistochemistry. 
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Vacuolation Scoring 
Brain sections from 4 infected and 2 mock-inoculated animals from each time-point (30, 
60, 90, 120, 155 DPI) were mounted and stained with hematoxylin and eosin. 15 regions of interest, 
12 grey matter and 3 white matter, were evaluated per animal and scored on a scale of 0 (no 
vacuoles) to 5 (maximal vacuolation) for grey matter and 0 to 3 for white matter, as described by 
Fraser and Dickinson (1973).  Scores were averaged among timepoint cohorts, and mean values 
≥2 (grey matter) and ≥1 (white matter) were considered definitive for spongiform change. Regions 
of interest analyzed for this and subsequent immunohistochemistry studies included the following, 
from caudal to rostral: vestibular nuclei (VestNuc), cerebellar peduncles (CerPed), cerebellar 
nuclei (CerNuc), superior colliculus (Coll), medial longitudinal fasciculus (MLF), midbrain 
reticular nucleus (MRN), lateral thalamus (LatThal), medial thalamus (MedThal), hypothalamus 
(Hypothal), dentate gyrus of hippocampus (HDG), CA1 of hippocampus (HCA1), internal capsule 
(IntCap), cerebral cortex at level of thalamus (Cthal), septal nuclei (SepNuc) and cerebral cortex 
at level of septal nuclei (Csep).  
 
Immunohistochemistry 
Brain sections were immunolabeled to detect PrPsc as previously described79 using mouse 
anti-PrP primary antibody 6C2 (CVI-WUR, Lelystad). Sequential multiple immunolabeling was 
performed on two sets of serial tissue sections using primary antibodies against Arg1 (rabbit anti-
Arg1, ab91279, Abcam), iNOS (rabbit anti-iNOS, ab15323, Abcam), Iba1 (rabbit anti-Iba1, 
ab178847, Abcam) and GFAP (rabbit anti-GFAP, Z022429, Dako). Each set was labeled first with 
either Arg1 or iNOS, followed by Iba1 and GFAP. For each set, slides were baked for 1h in a 60C 
oven and rehydrated. Antigen retrieval was performed in a rice cooker using citrate-EDTA-10% 
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w/v sucrose buffer (pH 6) for 15 minutes, followed by Tris-EDTA -10% w/v sucrose buffer (pH 
9) for 20 minutes. Next, sections were incubated for 10 minutes in a 3% hydrogen peroxide 
solution, followed by a 30 min incubation in 5% bovine serum albumin in Tris-buffered saline. 
iNOS and Arg1 primary antibodies were each applied at a dilution of 1:250, and incubated 
overnight at 4˚C. Tissues were then washed with TBST-10% w/v sucrose buffer, and incubated at 
37˚C with an HRP-conjugated goat anti-rabbit secondary antibody (ImmPRESS, MP-7500, Vector 
Laboratories) diluted 1:3 in TBST. After washing, slides were developed with ImmPACT AEC 
Peroxidase (HRP) Substrate (SK-4205, Vector Laboratories) according to kit instructions.  Tissues 
were counterstained with 1:1 deionized water:Gill’s #2 hematoxylin (Sigma-Aldrich) for 2 minutes 
and stored in TBS buffer at 4C through the duration of image acquisition. On completing image 
capture for each staining round, as described below, slides were stripped of chromogen and 
antibody by adapting a beta-mercaptoethanol buffer incubation protocol described by Gendusa et 
al. 24 as follows: doubling the concentration of beta-mercaptoethanol (1.8ml per 100ml buffer) and 
extending elution buffer incubation to 90 minutes.  After removing bound iNOS or Arg1 antibody 
complexes, tissues were re-blocked by incubating for 1 hour with 5% BSA in TBS, and then re-
labeled with rabbit anti-Iba1 primary (1:5000), as described above.  Following image acquisition 
of Iba1 immunoreactivity, tissues were again stripped of chromogen and antibody complexes, and 
submitted to a final round of immunolabeling for GFAP (1:5000).  On completing image capture, 
GFAP-stained slides were coverslipped with aqueous permanent mounting medium for long-term 
storage (VectaMount AQ, H-5501, Vector Laboratories). 
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Image Analysis  
Immunohistochemical staining was imaged using an Olympus DP73 camera mounted on 
an Olympus BX53 microscope, operated with cellSens imaging software (v1.15, Olympus 
Corporation). TBST-wetted slides were coverslipped and 4800x3600ppi brightfield images were 
acquired at 200x magnification for the medial thalamus and 400x magnification for the remaining 
14 regions of interest.  Following image capture, coverslips were gently floated off tissue sections 
and slides were returned to storage in TBST at 4C in anticipation of the next IHC round. Images 
of successive IHC rounds were acquired from the same subanatomic location by visually aligning 
nuclei. Captured images were processed using the Area Quantification module v1.0 within the 
HALO image analysis platform (v2.0.1145.19, Indica Labs).  Briefly, hematoxylin nuclear stain 
and AEC chromogen were selected as stain 1 and 2, respectively, and adequate deconvolution was 
confirmed visually.  A base threshold intensity value was assigned to image sets and manually 
adjusted, as needed, for each image to accurately reflect chromogen distribution in the regions of 
interest.  Total chromogen deposition in the region of interest was quantified by the module 
algorithm as % Stain 2 Positive Tissue. Colocalization of enzymatic and glial staining was 
achieved by assigning an opaque red and yellow pseudocolor to thresholded regions in HALO’s 
Area Quantification module, respectively, and importing the resulting .tif images into Photoshop 
CC (Adobe). The Layer Auto-Align command was used to overlay paired images from each region 
of interest.  An opacity value of 50% was assigned to the glial stain image, generating an orange 
zone in regions of colocalization. Layers were flattened, and the exported image was reanalyzed 
in HALO’s Area Quantification module v1.0 to obtain a % Stain Positive Tissue for the orange 
colocalization zone.   
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Statistical Analysis 
Data were analyzed using a generalized linear model to detect significant differences in 
quantified immunoreactivity between mock-inoculated and RML-infected animal groups. DPI, 
brain location and treatment condition were included as fixed effects in the model. Simple effect 
comparisons between the least squares (LS) means of mock-inoculated and infected animal groups 
were conducted at each DPI for each within all brain regions to determine the degree of 
significance. Similarly, simple effect comparisons were conducted between LS means of DPI 30 
and DPI 60, 90, 120, 155 within infected groups at each location.  These later comparisons were 
used to determine significance of increases in immunoreactivity in late disease at locations where 
the brain region of interest was not represented in mock-inoculated slides. Pearson correlation 
analysis was used to evaluate for temporal associations between stains at each location. Results 
were considered statistically significant if p<0.05. The software for conducting statistical analysis 
was SAS version 9.4. 
Results 
PrPsc deposition and spongiform change 
Infected animals developed classic neuropathologic changes of PrPsc accumulation and 
vacuolation (Fig. 1-5). Definitive spongiform change (Fig. 6) was first observed at 120 DPI in the 
three evaluated white matter regions (cerebellar peduncles, MLF, internal capsule), the lateral and 
medial thalamus, CA1 of the hippocampus and septal nuclei. By 155 DPI (clinical disease), 
spongiform change was additionally present in the vestibular nuclei and the dentate gyrus of the 
hippocampus.  Definitive vacuolation was not observed in other evaluated brain regions in infected 
animals, nor in control brains.   
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Quantitative immunohistochemistry was used to determine changes in PrPsc 
immunoreactivity over time. Significant increases between RML-infected and control groups were 
determined by one tail Student’s t-tests of simple effects comparisons between group least squares 
means.  PrPsc immunoreactivity (Fig. 7) was first significantly increased over age-matched 
controls at 60 DPI in the cerebellar nuclei (p<.05), midbrain reticular nucleus (MRN) ( p<.01 ), 
lateral thalamus (p<.05 ), septal nuclei (p<.05 ) and cortex at the level of the septal nuclei (p<.01).  
PrPsc remained progressively elevated through clinical disease in the cerebellar nuclei, MRN and 
lateral thalamus (p<.001). A significant and sustained increase in PrPsc immunoreactivity was first 
detected at 90 days in the vestibular nuclei (p<.01) and medial thalamus (p<.001), and a transient 
increase was detected in the hypothalamus (p<.01).  Significant PrPsc immunoreactivity was 
ubiquitous in all grey matter regions by 155 DPI (p<.001 for all brain regions, except hypothalamus 
p<.05).  PrPsc deposition in white matter tracts was minimal, only achieving significance above 
controls at 155 DPI in the MLF (p<.05) 
 
Gliosis 
 RML-inoculated animals developed microgliosis and astrocytosis over the course of 
infection. (Fig. 8-12)  Qualitative changes in microglial morphology were observed over the course 
of infection. (Fig. 13)  Quiescent ramified microglia were gradually replaced by hypertrophied 
phenotypes with thick processes, a change first observed in the MLF and, to a lesser degree, 
thalamus at 60 DPI. By 120 DPI, all examined regions contained a preponderance of hypertrophied 
microglia. Retraction of processes and a marked increase in somal volume (“amoeboid” microglia) 
was first observed at 120 DPI and sustained through clinical infection, where present.  This 
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morphology did not appear until 155 DPI in the hippocampus and never manifested in examined 
sections of the colliculus, hypothalamus, cortex or septal nuclei.  
Significant increases in Iba1 and GFAP immunoreactivity between infected and control 
animals were determined by one tail Student’s t-tests of simple effects comparisons between group 
least squares means.  In the absence of HCA1 representation in control slides at 155 DPI, RML-
inoculated animals were instead compared to the 30 DPI cohort.   
Iba1 immunoreactivity (Fig. 14) was significantly increased in infected brains as early as 
30 DPI in the cortex at the level of the thalamus (p>.05) and 60 DPI in the MLF (p<.05).  By 90 
DPI, significant upregulation was detected in the vestibular nuclei (p<.01), MLF (p<.001), MRN 
(p<.001), medial and lateral thalamus (p<.001), hypothalamus (p<.001), and cortex at the level of 
the thalamus (p<.05).  With exception of septal nuclei which failed to maintain significance at 
clinical disease (p=.0631), microgliosis was diffusely distributed through all brain regions by 155 
DPI (p<.001 for all brain regions, excepting p<.05 for hypothalamus).   
Astrocytic GFAP expression (Fig. 15) underwent a transient increase above age-matched 
controls at 60 DPI in the cerebellar peduncles (p<.05), HCA1 of the hippocampus (p<.01), and 
septal nuclei (p<.001).  Sustained upregulation was not observed until 90 DPI in the MLF (p<.001), 
MRN (p<.001), and medial and lateral thalamus (p<.001).  A significant increase in GFAP 
immunoreactivity was first detected at 120 DPI in the vestibular nuclei (p<.001), cerebellar nuclei 
(p<.001), colliculus (p<.001), cortex at the level of the thalamus (p<.001), and the cortex at the 
level of the septal nuclei (p<.05).  Increased labeling was not measured at any point in the dentate 
gyrus, internal capsule or hypothalamus.  The cerebellar peduncles, hippocampus, hypothalamus 
and internal capsule in control animals demonstrated elevated GFAP immunoreactivity at all 
timepoints relative to other brain regions.   
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Temporospatial distribution of iNOS and Arg1 
Quantitative IHC was similarly used to evaluate total iNOS and Arg1 immunoreactivity 
(Fig. 16-20) and the degree of colocalization with Iba1 and GFAP within each brain region. 
Significant differences in iNOS and Arg1 immunoreactivity between infected and control mice 
were determined by two tail Student’s t-tests of simple effects comparisons between group least 
squares means for total enzyme.  One tail Student’s t-tests were used to compare increases in 
colocalized enzyme expression between group least squares means. In the absence of HCA1 
representation in control slides at 155DPI, RML-inoculated animals were compared to the 30DPI 
cohort. 
Total iNOS expression was varied across the brain regions, with no significant change in 
infected mice in 7/15 regions (Fig. 21).  A transient increase in total iNOS was observed at 60 DPI 
in the vestibular nuclei (p<.01) and cerebellar nuclei (p<.01).  From 60-155 DPI, there was a 
sustained and progressive increase in iNOS in the cerebellar peduncles (p<.05). Expression was 
not significantly elevated until 120 DPI in the MLF (p<.01), MRN (p<.01), and lateral thalamus 
(p<.05).  Late increases in iNOS immunoreactivity were first observed at 155 DPI in CA1 of the 
hippocampus (p<.01, compared to 30 DPI infected cohort) and internal capsule (p<.001).  
To determine the degree of microglial and astrocytic expression of iNOS, colocalization of 
iNOS with Iba1 and GFAP was quantified (Fig. 22). iNOS colocalized primarily with microglial 
Iba1. (Fig. 23).  A significant increase in colocalization of Iba1 with iNOS was first observed at 
120 DPI in the vestibular nuclei (p<.05), MLF (p<.001), MRN (p<.001) and internal capsule 
(p<.01).  By 155 DPI, microglial iNOS was upregulated in 9/15 brain regions, including the 
vestibular nuclei (p<.001), cerebellar peduncles (p<.001), cerebellar nuclei (p<.001), MLF 
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(p<.001), MRN (p<.001), lateral thalamus (p<.001), medial thalamus (p<.05), CA1 (p<.05, 
compared to 30 DPI infected cohort) and the internal capsule (p<.001).   A significant increase in 
colocalization of iNOS and GFAP was present only at 155 DPI in the white matter tracts of the 
cerebellar peduncles (p<.001) and the internal capsule (p<.001), with a transient increase at 120 
DPI in the lateral thalamus (p<.05) (Fig. 24). iNOS immunoreactivity that did not colocalize with 
either Iba1 or GFAP was primarily observed along vascular endothelium and forming halos around 
small nuclei of uncertain cellular identity.   
Total Arg1 expression demonstrated no statistically significant change over time in the 
majority (13/15) of evaluated brain regions (Fig. 25).  Vestibular nuclei displayed increased Arg1 
immunoreactivity over controls at 30 DPI (p<.05). A significant decrease in Arg1 was detected in 
this region at 120 DPI (p<.001); however, this was likely due to one outlying control value that 
contained a concentration of strongly Arg1-immunoreactive neurons.  Cerebellar nuclei displayed 
a similar transient increase in Arg1 expression at 30 DPI (p<.05) and another significant increase 
at 155 DPI (p<.001).   
To determine the degree of microglial and astrocytic expression of Arg1, colocalization of 
Arg1 with Iba1 and GFAP was quantified. In areas of highest Arg1 expression, such as the medulla 
oblongata and cerebellum, neuronal and vascular Arg1 expression accounted for the majority of 
immunoreactivity (Fig. 26).  Overall, the amount of glial Arg1 expression was low, but Arg1 
colocalized to a greater extent with astrocytic GFAP than microglial Iba1. Low quantities of Arg1 
colocalization with Iba1 were detected at significant levels over controls in the vestibular nuclei at 
90 (p<.01) and 120DPI (p<.05) (Fig. 28).  A similar increase in Iba1-colocalized Arg1 at 120DPI 
(p<.05) with concurrent increases in control and clinical animals at 155DPI was observed in the 
cerebellar peduncles. Iba1-colocalized Arg1 expression was significantly increased at 120 (p<.05) 
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and 155DPI (p<.001) in the cerebellar nuclei.  Microglial Iba1 colocalization represented a fraction 
of total glial Arg1.  At such low levels of quantified coreactivity, incidental overlap (e.g. overlap 
of neuronal cytoplasm and microglial process) could be a confounding factor for meaningful 
interpretation.  GFAP colocalization with Arg1 represented the majority of glial 
coimmunoreactivity (Fig 27).  A significant increase in astrocytic expression of Arg1, beginning 
at 120DPI and sustained through clinical disease, was observed in the vestibular nuclei (p<.01), 
cerebellar peduncles (p<.05), and cerebellar nuclei (p<.05)  (Fig. 29). Astrocytic Arg1 was 
transiently upregulated at 120DPI in the medial thalamus (p<.01), dentate gyrus (p<.05) and CA1 
(p<.01). Although trends towards sustained upregulation of astrocytic Arg1 at 120DPI were 
observed in the colliculus and MRN, and suggestions of a transient elevation at 120DPI were 
present in the lateral thalamus, internal capsule and septal nuclei, the quantified signal did not 
achieve statistical significance over controls.  
 
 
Correlation analysis between immunohistochemical stains 
 To determine whether iNOS and Arg1 immunoreactivity is correlated to regional 
neuropathology development, Pearson’s correlation matrices were calculated for 
immunohistochemical stains at each location in infected mice (Table A1).  Additionally, iNOS and 
Arg1 were compared to each other at each location to identify any relationship between expression 
patterns of this mutually inhibitory enzyme pair. Stain pairs with r>|.8| were evaluated as having a 
strong linear relationship. Only relationships with p<.05 are presented below. All significant 
relationships observed in this model displayed a positive correlation. It is important to note that 
because r values do not reflect the slope of temporal trends in immunoreactivity, some strong 
positive correlations corresponded to an absence of change for both stains at the analyzed location.   
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Total iNOS exhibited positive correlations at the largest number of locations with PrPsc and 
Iba1, and displayed less association with spongiform change and GFAP.  Immunoreactivity was 
positively associated over time with PrPsc in the cerebellar peduncles (p<.05), dentate gyrus 
(p<.001), CA1 (p<.001), internal capsule (p<.001) and the cortex at the level of the thalamus 
(p<.05).  Little significant interaction was present between total iNOS and vacuolation, as a 
positive relationship was observed only in 2/9 locations that developed spongiform change.  These 
included the MLF and the dentate gyrus (p<.05 for both).  Total iNOS was positively associated 
with Iba1 in the cerebellar peduncles (p<.05), lateral thalamus (p<.05), hippocampus (p<.05) and 
internal capsule (p<.05).   A positive correlation between total iNOS and GFAP was observed only 
in the MLF, CA1 and cortex at the level of the thalamus (p<.05 for all).  
Microglial iNOS displayed little difference in the strength of association with PrPsc and 
glial stains, as positive correlations were observed in 4-5 scattered brain regions for any stain pair.  
Microglial iNOS was moderately correlated to spongiform change.  Positive relationships were 
observed in 4/9 areas where definitive vacuolation was present, including the vestibular nuclei, the 
cerebellar peduncles, MLF, and internal capsule (p<.05 for all). A positive correlation was 
observed with PrPsc deposition in 5/9 areas, including the vestibular nuclei (p<.05), cerebellar 
peduncles (p<.01), medial thalamus (p<.05), CA1 of the hippocampus (p<.01) and the internal 
capsule (p<.001).  Astrocytic iNOS was positively correlated to spongiform change in only 3/9 
areas with definitive vacuolation, including the medial (p<.01) and lateral (p<.01) thalamus and 
CA1 (p<.05).  Sporadic associations were observed with PrPsc in 3 brain regions.  
Total Arg1 displayed marginally more association with spongiform change and Iba1, 
compared to PrPsc and GFAP.  Total Arg1 was positively correlated to PrPsc in 4/15 regions, 
including the vestibular nuclei (p<.05), cerebellar peduncles (p<.05), colliculus (p<.05), and cortex 
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at the level of the thalamus (p<.001).  Arg1 was positively correlated to spongiform change in 5/9 
brain regions that developed definitive vacuolation. These included the vestibular nuclei (p<.05), 
cerebellar peduncles (p<.05), medial and lateral thalamus (p<.05) and the dentate gyrus (p<.01).  
Of the glial stains, total Arg1 displayed the most correlation with Iba1 immunoreactivity.  Despite 
only displaying statistically significant increases in immunoreactivity in the vestibular and 
cerebellar nuclei, total Arg1 was additionally positively correlated to Iba1 in the colliculus (p<.05), 
medial and lateral thalamus (p<.05), dentate gyrus (p<.001) and cortex at the level of the thalamus 
(p<.05).  Significant positive correlation with GFAP was observed only in the colliculus (p<.001), 
MLF (p<.05) and hypothalamus (p<.001).  
Microglial Arg1 represented a minor fraction of glial colocalization, but displayed strong 
positive correlation with PrPsc in 6/15 brain regions and with spongiform change in 5/9 regions 
where vacuolation was definitively observed.  Astrocytic Arg1 displayed markedly less association 
with PrPsc  deposition and spongiform change, with positive correlation observed in only 2/15 and 
1/9 regions, respectively.   
Correlation coefficients between total iNOS and Arg1 were evaluated for evidence of 
reciprocal trends.  Overall, there was little correlation between global enzyme expression across 
brain regions, as only the MLF and thalamus displayed a strong positive relationship between total 
iNOS and Arg1 (p<.05).  Interestingly, despite apparently strong positive correlation in 
immunoreactivity between total enzymatic stains in the MLF (p<.05, n=5), no association between 
iNOS and glial Arg1 was observed in this region.  No significant negative linear relationships 
between total iNOS and Arg1 were present in these data. There were few significant interactions 
between glial Arg1 and glial iNOS across the brain.  No reciprocal relationships suggestive of 
temporal inhibition were observed between glia-colocalized stains.  
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Discussion 
 
This study sought to characterize the temporospatial distribution of salient prion 
neuropathology in an intracranial infection model of murine scrapie and correlate changes to 
canonical markers of glial polarization.   
Prion infection is known to induce a patterned progression of neuropathology in the brain, 
wherein PrPsc accumulation is followed by glial activation and finally by spongiform change, 
neuronal and synaptic loss.11, 80  While this infection model reproduced histologic changes 
classically associated with scrapie infection, the order of lesion development deviated somewhat 
from previous reports.  
In the present work, PrPsc deposition preceded gliosis in 4/15 regions, and was the first 
pathologic change observed at 60DPI in the cerebellar nuclei, lateral thalamus, and rostral cortex, 
with delayed detection at 120DPI in the dentate gyrus.  In the remaining regions, gliosis was 
detected either in advance of, or contemporaneously with the first significant increases in PrPsc 
immunoreactivity between 60 and 90DPI.   
Astrocytic accumulation of PrPsc has been demonstrated early in disease progression,21, 72 
and previous works have detected an upregulation of GFAP as early as 40DPI,11 well in advance 
of microgliosis.11  Astrocytosis was detected at 60DPI prior to microgliosis in only 4/15 of the 
evaluated brain regions, including the cerebellar peduncles, midbrain reticular nucleus (MRN), 
CA1 and septal nuclei.  In remaining regions, microgliosis either preceded or was detected at the 
same time as the first appreciable increase in GFAP immunoreactivity.  Notably, in the vestibular 
nuclei, MLF, internal capsule, and cortex at the level of the thalamus, microgliosis was 
quantifiably increased before upregulation of either GFAP or PrPsc immunoreactivity.  The timing 
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and distribution of prion-associated neurodegenerative changes are dictated by incompletely 
understood strain-host interactions, but are highly conserved within an infection model.23  Our 
demonstration of a precocious microglial response relative to other studies that employed RML 
scrapie agent in C57BL/6 mice11 may be attributed to variations in harvest timepoints, sampling 
location or genetic polymorphisms arising from the long-term (>20 generations) inbreeding of the 
originating colony.49  
Spongiform change, where detected, occurred subsequent to PrPsc deposition and gliosis, 
consistent with RML progression in other models.  In the 9 areas where definitive vacuolation was 
detected, spongiform change had the highest degree of correlation with Iba1 immunoreactivity, 
exhibiting a strong positive relationship with 8/9 brain regions, excepting the MLF. A lesser degree 
of association was observed between spongiform change, PrPsc and Arg1, with 5/9 regions of each 
of these stains exhibiting strong positive relationships with vacuolation. In contrast GFAP only 
demonstrated strong positive correlation with vacuolation in 3/9 areas, including the vestibular 
nuclei, lateral thalamus and cortex at the level of the septal nuclei.  These findings suggest that 
microgliosis is more strongly associated with development of spongiform change than 
astrocytosis.   
Neuropathology was most pronounced in the dorsal medulla, sensory midbrain and the 
thalamus.  These regions demonstrated marked PrPsc accumulation and gliosis by 90 days post-
inoculation, with the MRN exhibiting PrPsc accumulation and astrocytosis by 60DPI.  Of the 15 
evaluated brain regions, the hypothalamus exhibited the least pathology, with only a transient 
increase in PrPsc and Iba1 at 90DPI, and a second, smaller, peak for both at 155DPI.   
The hippocampus, a region commonly evaluated in experimental prion infection due to its 
involvement in behavioral alterations, exhibited a relatively late onset of lesion development and 
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inconsistent pathology between the closely apposed dentate gyrus and CA1.  Delayed PrPsc 
accumulation was the first indicator of pathology in the dentate gyrus at 120 DPI, with spongiform 
change and upregulation of Iba1 appearing at 155DPI.  No significant astrocytosis was detected in 
this region.  CA1, however, exhibited an early transient spike in GFAP at 60 DPI (p<.01), which 
was followed by microgliosis and spongiform change at 120DPI.  PrPsc deposition did not achieve 
significant levels and GFAP upregulation wasn’t observed again in the CA1 until 155DPI (p<.001 
for both).   
 The neuroinflammatory profile of prion disease has been a subject of continued debate, 
and published results vary with infection model.54  Several studies have reported that prion 
infection incites a marked upregulation of genes mediating cell motility, proliferation, homeostatic 
mechanisms and inflammatory responses that are primarily attributed to microglia.3, 65  
Furthermore, two patterns of upregulation were detected: non-lesioned areas were associated with 
a homeostasis-mediating cluster, while lesioned brain regions overexpressed genes related to 
proteolysis, cell stress and activation of innate immunity.3, 73  This apparent dichotomy in 
microglial activation profiles lends support for the potential benefits of localized in-situ analysis.  
Infected brains in recent comprehensive transcriptomic and cytokine array analyses demonstrated 
a definitively proinflammatory signature, with upregulation of IL1β, TNFα, Csf1, IFNγ, caspase 
4, TIMP1 and MMP12.10, 51, 53, 64, 71, 73  Such an inflammatory milieu would be anticipated to 
promote pro-inflammatory polarization of microglia and induce iNOS expression.58  Indeed, 
microglia have been shown to elaborate nitric oxide in response to PrPsc.30  However, phagocytosis 
of apoptotic neurons in late disease38 could bias microglia towards alternative activation, which is 
associated with Arg1 expression.68    Mixed populations of microglia mediating pro-and anti-
inflammatory effects have been demonstrated in Alzheimer’s disease14, 48 and ALS44.  We used 
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quantitative immunohistochemistry to spatiotemporally characterize iNOS and Arg1 labeling 
through the infection timecourse and correlate expression to lesion patterns.  Colocalization 
analysis of enzyme immunoreactivity with Iba1 and GFAP was furthermore employed to 
differentiate between microglial and astrocytic expression.  
iNOS induction in the brain results in elaboration of neuronotoxic nitric oxide (NO).7  
iNOS expression is associated with classically activated proinflammatory glia15, 34, and has been 
demonstrated in AD48, 76, PD37, 70  and ALS62.  Total iNOS expression was upregulated late in 
disease incubation, with significantly increased expression detected by 120 DPI in 4/15 regions 
and in an additional 4 locations at terminal disease, representing the dorsal medulla, cerebellum, 
midbrain, lateral thalamus, HCA1 and internal capsule. No iNOS upregulation was observed in 
the colliculus, medial thalamus, hypothalamus, dentate gyrus, septal nuclei or cerebral cortex.  It 
is notable that closely apposed regions, such as the dentate gyrus and CA1 of the hippocampus, 
and the medial and lateral thalamus had statistically significant variation in iNOS expression.  
Among brain regions exhibiting iNOS upregulation, the strongest positive correlation between 
iNOS and other immunohistochemical targets was observed with Iba1, a finding supported by 
colocalization data.  Additionally, neither total nor microglial iNOS upregulation was detected in 
brain regions that failed to demonstrate a transition to amoeboid microglial morphology by clinical 
disease. These included the colliculus, hypothalamus, dentate gyrus, septal nuclei and both cortical 
locations.  iNOS detection in this model contrasts with previous reports detailing lack of iNOS 
upregulation77 or transient upregulation followed by descending expression in terminal disease.12  
However, these studies used ME7 scrapie, which has been associated with a dampened 
inflammatory profile, 6, 18 and analyzed signal from whole or partially dissected brain homogenate.    
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The spatial distribution of iNOS expression in our model supports the possibility of signal dilution 
as a confounding factor in these study designs.  
iNOS immunoreactivity was observed to colocalize with both Iba1 and GFAP.  Significant 
increases in microglial iNOS expression were observed by 155 DPI in all regions of global iNOS 
upregulation, with the addition of medial thalamus.  Increased astrocytic iNOS expression was 
only observed in white matter of the cerebellar peduncles and internal capsule. Curiously, a 
concomitant increase in total GFAP immunoreactivity was not observed in the internal capsule at 
155 DPI.  Inversely, there is a lack of significant astrocytic iNOS at 155 DPI in the MLF, despite 
marked GFAP upregulation as early as 90 DPI.  Combined, these findings indicate that astrocytic 
iNOS induction is not directly associated with the density of activated fibrous astrocytes and is 
driven by unknown location-dependent factors.  Sporadic iNOS immunoreactivity was also 
observed in GFAP- and Iba1-negative cells with filamentous processes that strongly resembled 
astrocytes.  GFAP has been demonstrated to underestimate astrocyte densitiy36, as it can fail to 
label up to 40% of cells78 and only associates with an estimated 15% of total cell volume9.  Thus, 
the colocalization results may not fully reflect astrocytic contribution to iNOS expression.  In sum, 
our results support the existence of a pro-inflammatory iNOS-high environment primarily 
generated by microglia at clinical disease.  This is consistent with an M1 “classically activated” 
microglial phenotype.  
Expression of Arg1, used to identify M2 microglia,15 is associated with extracellular matrix 
repair, suppression of inflammation, and has been demonstrated in both astrocytes and monocytes 
during the reparative phase of spinal cord injury.2, 52, 68   Arginase-1 expression did not reflect the 
same widespread distribution as iNOS and displayed markedly different cell association.  Global 
Arg1 expression was unremarkable rostral to cerebellum.  The highest immunoreactivity levels 
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were noted in the grey matter regions of the dorsal medulla and cerebellum, in control and infected 
animals alike, relative to the rest of the brain. Here, Arg1 immunoreactivity was primarily observed 
in neuronal cytoplasm with variable expression in vascular endothelium.  This finding coincides 
with Yu et al.’s report of high basal arginase expression in the grey matter of the cerebellum and 
dorsal medulla, however hippocampal and cerebral cortical immunoreactivity was not 
recapitulated in the present timecourse.81  In this study, as in ours, Arg1 was primarily expressed 
by neurons.81 
In areas with significant Arg1 upregulation, glial expression colocalized predominantly 
with GFAP.  In-situ colocalization permitted detection of a small but statistically significant 
transient rise in astrocytic Arg1 at 120 DPI in the medial thalamus, dentate gyrus and CA1 of the 
hippocampus, areas where there was no concurrent increase in total or microglial Arg1, and no 
hippocampal GFAP upregulation.  Activated astrocytes can elaborate either neurotrophic factors 
promoting repair, or pro-inflammatory synaptolytic compounds, depending on the nature of the 
activating stimulus.34, 63, 82  An activation spectrum similar to the M1/M2 paradigm has been 
advanced for astrocytes, broadly characterizing neurotoxic “A1” and neuroprotective “A2” 
phenotypes.45  Arg1 production has been demonstrated in healthy and reactive astrocytes in a 
model of spinal cord trauma,2 and can be induced in experimental polarization of cultured 
astrocytes.34  Analysis of tissues from patients with protein misfolding neurodegenerative diseases 
including AD, HD, PD and ALS demonstrated presence of proinflammatory A1 astrocytes in 
lesioned brain regions.46 Previous reports of astrocytic response to prion infection have similarly 
demonstrated a pro-inflammatory phenotype with secretion of IL1β, IL6, IL12 and TNFα,64, 71 thus 
our finding of predominantly astrocytic Arg1 expression associated with an anti-inflammatory 
profile is unexpected.  
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Interestingly, total Arg1 exhibited a strong positive relationship with spongiform change 
in 5/9 regions where definitive spongiform change was detected. However, this relationship was 
not reflected by astrocytic Arg1, which was only positively correlated with spongiform change in 
the cerebellar peduncles.  A strong positive correlation was similarly observed with microglial 
Arg1, however, Iba1-Arg1 colocalization represented an exceedingly small fraction of total Arg1 
expression, suggesting that increased neuronal, rather than glial, expression contributed to any 
potential causality in this relationship.  Additionally, on retrospective image analysis of regions 
with increased calculated Iba1-Arg1, colocalization frequently corresponded to areas of high 
neuronal density and could be attributed to coincidental overlap of cell processes and neurons, 
rather than true colocalization within a single glial species.  Study design did not accommodate 
case-by-case exclusion of incidental colocalization.  Thus, the Arg1-Iba1 colocalization data may 
not present significant evidence of an M2-polarized population.   
iNOS and Arg1 exert opposing effects on the inflammatory status of surrounding cells.  
The possible association between expression of these enzymes and progression of regional 
pathology was explored through correlation analysis.  Positive relationships were identified 
between iNOS/Arg1 and markers of neuropathology and gliosis at sporadic locations, however 
overwhelming evidence that either enzyme is more strongly associated with lesion development 
on a global scale was not present in our data.   
Arg1 and iNOS rely on arginine metabolism and are mutually inhibitory, both through 
substrate competition and suppressive effects of downstream metabolites.57  In the present study, 
an inverse temporal relationship between total NOS and Arg1 was not observed at any location.  
Furthermore, immunoreactivity was largely segregated by cell type, with significant coexpression 
of both Arg1 and iNOS in one glial population limited to astrocytes in the cerebellar peduncles.  
62 
 
Although transient upregulation of astrocytic Arg1 at 120 DPI was detected in several locations, 
these observations were not paired with a reciprocal rise in astrocytic iNOS at 155 DPI.  Thus, 
there is no evidence that suppression of astrocytic Arg1 in clinical disease is mediated by iNOS.    
In summary, our data support strong spatiotemporal associations between lesion 
development and proliferation of microglia demonstrating a pro-inflammatory iNOS-high 
phenotype.  In contrast, astrocytic iNOS expression appears limited to cerebellar and diencephalic 
white matter, with trends towards anti-inflammatory Arg1 production in medullary and cerebellar 
regions, and transient upregulation in the diencephalon in late incubation.  To our knowledge, this 
timecourse represents the first in-situ characterization of glial immunophenotypes in RML scrapie 
infection using sequential chromogenic immunohistochemistry.  Our findings corroborate 
previous reports of a predominantly pro-inflammatory microglial profile in prion infection and 
contribute new evidence of location-dependent mixed astrocytic activation.   
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Figures and Figure Legends 
Figures 1-5.  Representative images of thalamic vacuolation and PrPsc immunoreactivity in RML-
infected murine brain at 30 (Figure 1), 60 (Figure 2), 90 (Figure 3), 120 (Figure 4) and 155 DPI 
(Figure 5).  Figures 1a-5a  Definitive spongiform change, characterized by well-demarcated empty 
vacuoles, was first detected at 120 DPI (4a).  Histologic sections of thalamus, 400x, H&E.  Figures 
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1b-5b. Immunohistochemistry for PrPsc, monoclonal antibody 6C2.  PrPsc labeling first appears 
at 60 DPI (2b) as punctate to granular immunoreactivity. Lateral thalamus, 400x, DAB. 
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Figure 6.  Neuronal vacuolation scores of RML-infected mice in grey (A) and white matter (B) 
regions over time.  Data points for each brain region represent simple means for integer scores 
assigned to RML-infected cohorts at each timepoint.  A. Grey matter vacuolation for a brain region 
was considered definitive for spongiform change when sample means ≥2, observed first at 120 
DPI.  B. White matter vacuolation was considered definitive for spongiform change when sample 
means ≥1; observed in all 3 regions at 120 DPI. Vestibular nuclei (VestNuc), cerebellar peduncles 
(CerPed), cerebellar nuclei (CerNuc), superior colliculus (Coll), medial longitudinal fasciculus 
(MLF), midbrain reticular nucleus (MRN), lateral thalamus (LatThal), medial thalamus 
(MedThal), hypothalamus (Hypothal), dentate gyrus of hippocampus (HDG), CA1 of 
hippocampus (HCA1), internal capsule (IntCap), cerebral cortex at level of thalamus (Cthal), 
septal nuclei (SepNuc), cerebral cortex at level of septal nuclei (Csep). 
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Figure 7.  PrPsc immunoreactivity in 15 brain regions over RML infection timecourse.  Bars 
represent mean±SE values for control (C) and RML-inoculated (I) animal cohorts at each 
timepoint (30, 60, 90, 120, 155 DPI).  *p < 0.05, **p < 0.01, ***p < 0.001; significant differences 
compared with control animals.  Vestibular nuclei (VestNuc), cerebellar peduncles (CerPed), 
cerebellar nuclei (CerNuc), superior colliculus (Coll), medial longitudinal fasciculus (MLF), 
midbrain reticular nucleus (MRN), lateral thalamus (LatThal), medial thalamus (MedThal), 
hypothalamus (Hypothal), dentate gyrus of hippocampus (HDG), CA1 of hippocampus (HCA1), 
internal capsule (IntCap), cerebral cortex at level of thalamus (Cthal), septal nuclei (SepNuc), 
cerebral cortex at level of septal nuclei (Csep). 
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Figures 8-12. Representative images of Iba1 and GFAP immunoreactivity in the thalamus of 
infected mice 30 (Figure 8), 60 (Figure 9), 90 (Figure 10), 120 (Figure 11) and 155 DPI (Figure 
12).  Figures 8a-12a. Microglia undergo a hypertrophic and hyperplastic response to prion 
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infection at later timepoints, first appreciated here at 90 DPI (10a). Lateral thalamus, 400x, IHC 
for Iba1, AEC.  Figures 8b-12b.  Proliferative astrocytic reaction to scrapie infection visible at 90 
DPI (10b). Lateral thalamus, 400x, IHC for GFAP, AEC.   
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Figure 13.  Temporal changes in microglial morphology in response to prion infection.  
Representative images of ramified quiescent microglia (13a, control thalamus, 155 DPI), 
hypertrophied microglia (13b, RML-infected hippocampus, 120 DPI) and amoeboid microglia 
(13c, RML-infected cerebellar nuclei, 155 DPI).  400x, IHC for Iba1, AEC. Table documents 
appearance of hypertrophied and amoeboid microglial populations over time across 15 brain 
regions.  Columns represent a single RML-infected animal at each collection timepoint.   .  - only 
ramified microglia observed.   H -  hypertrophied microglia present. HA - both hypertrophied and 
amoeboid microglia present.       - Brain region not present in tissue section.  
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Figure 14.  Iba1 immunoreactivity in 15 brain regions over RML infection timecourse.  Iba1 
labeling quantified in brain regions as % tissue positive for Iba1 immunoreactivity.  Bars represent 
mean ±SE values for control (C) and RML-inoculated (I) animal cohorts at each sacrifice 
timepoint.  *p < 0.05, **p < 0.01, ***p < 0.001; significant differences compared with control 
animals. *** p<.001, significant difference compared to 30DPI RML-infected animals.  Vestibular 
nuclei (VestNuc), cerebellar peduncles (CerPed), cerebellar nuclei (CerNuc), superior colliculus 
(Coll), medial longitudinal fasciculus (MLF), midbrain reticular nucleus (MRN), lateral thalamus 
(LatThal), medial thalamus (MedThal), hypothalamus (Hypothal), dentate gyrus of hippocampus 
(HDG), CA1 of hippocampus (HCA1), internal capsule (IntCap), cerebral cortex at level of 
thalamus (Cthal), septal nuclei (SepNuc), cerebral cortex at level of septal nuclei (Csep). 
78 
 
 
Figure 15.  GFAP immunoreactivity in 15 brain regions over RML infection timecourse.  GFAP 
labeling quantified in brain regions as % tissue positive for AEC chromogen deposition.  Bars 
represent mean±SE values for control (C) and RML-inoculated (I) animal cohorts at each sacrifice 
timepoint.  *p < 0.05, **p < 0.01, ***p < 0.001; significant differences compared with control 
animals. *** p<.001, significant difference compared to 30DPI RML-infected animals. Vestibular 
nuclei (VestNuc), cerebellar peduncles (CerPed), cerebellar nuclei (CerNuc), superior colliculus 
(Coll), medial longitudinal fasciculus (MLF), midbrain reticular nucleus (MRN), lateral thalamus 
(LatThal), medial thalamus (MedThal), hypothalamus (Hypothal), dentate gyrus of hippocampus 
(HDG), CA1 of hippocampus (HCA1), internal capsule (IntCap), cerebral cortex at level of 
thalamus (Cthal), septal nuclei (SepNuc), cerebral cortex at level of septal nuclei (Csep). 
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Figures 16-20. Representa tive images of iNOS and Arg1 immunoreactivity in the thalamus of 
infected mice 30 (Figure 16), 60 (Figure 17), 90 (Figure 18), 120 (Figure 19) and 155 DPI (Figure 
20).  16a-20a. Immunohistochemistry for iNOS.  Occasional immunoreactivity in endothelium. 
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Filamentous labeling reminiscent of glial processes present at later timepoints (insets, 19-20a).  
Lateral thalamus, 400x, AEC. 16b-20b. Immunohistochemistry for Arg1. Faint linear and neuronal 
cytoplasmic labeling present in late timepoints (insets, 19-20b). Lateral thalamus, 400x, AEC.   
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Figure 21.   Total iNOS immunoreactivity in 15 brain regions over RML infection timecourse. 
Bars represent mean±SE values for mock-inoculated (C) and RML-inoculated (I) animal cohorts 
at each sacrifice timepoint.  *p < 0.05, **p < 0.01, ***p < 0.001; significant differences compared 
with control (mock-inoculated) animals. ** p<.01, significant difference compared to 30 DPI 
infected. Vestibular nuclei (VestNuc), cerebellar peduncles (CerPed), cerebellar nuclei (CerNuc), 
superior colliculus (Coll), medial longitudinal fasciculus (MLF), midbrain reticular nucleus 
(MRN), lateral thalamus (LatThal), medial thalamus (MedThal), hypothalamus (Hypothal), 
dentate gyrus of hippocampus (HDG), CA1 of hippocampus (HCA1), internal capsule (IntCap), 
cerebral cortex at level of thalamus (Cthal), septal nuclei (SepNuc), cerebral cortex at level of 
septal nuclei (Csep). 
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Figure 22.  iNOS colocalization with Iba1 and GFAP in a clinical RML-infected mouse, MRN, 
representative image.  Sequential immunohistochemical labeling for iNOS (22a), Iba1 (22b), and 
GFAP (22c) was performed on the same section of brain. iNOS colocalizes with Iba1 (22d), but 
fails to demonstrate overlap with GFAP expression in this section (22e).  Red – iNOS; yellow – 
Iba1, 22d; GFAP, 22e; orange – colocalization of iNOS and glial labeling.  MRN, 400x, 
immunohistochemistry. 
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Figure 23.   iNOS colocalization with Iba1 in 15 brain regions over RML infection timecourse. 
Colocalization was quantified in brain regions as % tissue positive for both iNOS and Iba1 
immunoreactivity in composite images.  Bars represent mean±SE values for mock-inoculated (C) 
and RML-inoculated (I) animal cohorts at each sacrifice timepoint.  *p < 0.05, **p < 0.01, 
***p < 0.001; significant differences compared with control (mock-inoculated) animals. * p<.05, 
significant difference compared to 30 DPI RML-infected animals. Vestibular nuclei (VestNuc), 
cerebellar peduncles (CerPed), cerebellar nuclei (CerNuc), superior colliculus (Coll), medial 
longitudinal fasciculus (MLF), midbrain reticular nucleus (MRN), lateral thalamus (LatThal), 
medial thalamus (MedThal), hypothalamus (Hypothal), dentate gyrus of hippocampus (HDG), 
CA1 of hippocampus (HCA1), internal capsule (IntCap), cerebral cortex at level of thalamus 
(Cthal), septal nuclei (SepNuc), cerebral cortex at level of septal nuclei (Csep). 
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Figure 24.   iNOS colocalization with GFAP in 15 brain regions over RML infection timecourse. 
Colocalization was quantified in brain regions as % tissue positive for both iNOS and GFAP 
immunoreactivity in composite images.  Bars represent mean±SE values for mock-inoculated (C) 
and RML-inoculated (I) animal cohorts at each sacrifice timepoint.  *p < 0.05, **p < 0.01, 
***p < 0.001; significant differences compared with control (mock-inoculated) animals. 
Vestibular nuclei (VestNuc), cerebellar peduncles (CerPed), cerebellar nuclei (CerNuc), superior 
colliculus (Coll), medial longitudinal fasciculus (MLF), midbrain reticular nucleus (MRN), lateral 
thalamus (LatThal), medial thalamus (MedThal), hypothalamus (Hypothal), dentate gyrus of 
hippocampus (HDG), CA1 of hippocampus (HCA1), internal capsule (IntCap), cerebral cortex at 
level of thalamus (Cthal), septal nuclei (SepNuc), cerebral cortex at level of septal nuclei (Csep). 
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Figure 25.   Total Arg1 immunoreactivity in 15 brain regions over RML infection timecourse. 
Bars represent mean±SE values for control (C) and RML-inoculated (I) animal cohorts at each 
sacrifice timepoint.  *p < 0.05, **p < 0.01, ***p < 0.001; grey ***p<.001 represents negative 
difference between C and I means due to outlier in control brains. Significant differences compared 
with control animals. Vestibular nuclei (VestNuc), cerebellar peduncles (CerPed), cerebellar 
nuclei (CerNuc), superior colliculus (Coll), medial longitudinal fasciculus (MLF), midbrain 
reticular nucleus (MRN), lateral thalamus (LatThal), medial thalamus (MedThal), hypothalamus 
(Hypothal), dentate gyrus of hippocampus (HDG), CA1 of hippocampus (HCA1), internal capsule 
(IntCap), cerebral cortex at level of thalamus (Cthal), septal nuclei (SepNuc), cerebral cortex at 
level of septal nuclei (Csep). 
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Figure 26.   Arg1 colocalization with Iba1 and GFAP in the vestibular nucleus from a clinical 
RML-infected mouse, representative image.  Sequential immunohistochemical labeling for Arg1 
(26a), Iba1 (26b), and GFAP (26c) was performed on the same section of RML-infected murine 
brain. Arg1 is largely expressed in neuronal cytoplasm, and fails to demonstrate significant overlap 
with either Iba1 (26d) or GFAP (26e) labeling in this section.  Red – Arg1 labeling.  Yellow – glial 
cytoplasmic protein labeling (Iba1, 26d; GFAP, 26e). Orange – colocalization of Arg1 and glial 
labeling.  Vestibular nucleus, 400x, immunohistochemisty.   
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Figure 27.  Arg1 colocalization with Iba1 and GFAP in a single hippocampal section from a 
120DPI RML-infected mouse, representative image.  Sequential immunohistochemical labeling 
for Arg1 (27a), Iba1 (27b), and GFAP (27c) was performed on the same section of RML-infected 
murine brain. Here, Arg1 fails to demonstrate overlap with Iba1 labeling (27d), but displays 
colocalization with GFAP expression (27e).  Red – Arg1 labeling.  Yellow – glial cytoplasmic 
protein labeling (Iba1, 27d; GFAP, 27e). Orange – colocalization of Arg1 and glial labeling (here, 
only in 27e).  CA1 of hippocampus, 400x, mmunohistochemistry.  
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Figure 28.   Arg1 colocalization with Iba1 in 15 brain regions over RML infection timecourse. 
Colocalization was quantified in brain regions as % tissue positive for both Arg1 and Iba1 
immunoreactivity in composite images.  Bars represent mean±SE values for control (C) and RML-
inoculated (I) animal cohorts at each sacrifice timepoint.  *p < 0.05, **p < 0.01, ***p < 0.001; 
significant differences compared with control animals.  Vestibular nuclei (VestNuc), cerebellar 
peduncles (CerPed), cerebellar nuclei (CerNuc), superior colliculus (Coll), medial longitudinal 
fasciculus (MLF), midbrain reticular nucleus (MRN), lateral thalamus (LatThal), medial thalamus 
(MedThal), hypothalamus (Hypothal), dentate gyrus of hippocampus (HDG), CA1 of 
hippocampus (HCA1), internal capsule (IntCap), cerebral cortex at level of thalamus (Cthal), 
septal nuclei (SepNuc), cerebral cortex at level of septal nuclei (Csep). 
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Figure 29.  Arg1 colocalization with GFAP in 15 brain regions over RML infection timecourse. 
Colocalization was quantified in brain regions as % tissue positive for both Arg1 and GFAP 
immunoreactivity in composite images.  Bars represent mean±SE values for control (C) and RML-
inoculated (I) animal cohorts at each sacrifice timepoint.  *p < 0.05, **p < 0.01, ***p < 0.001; 
significant differences compared with control animals.  Vestibular nuclei (VestNuc), cerebellar 
peduncles (CerPed), cerebellar nuclei (CerNuc), superior colliculus (Coll), medial longitudinal 
fasciculus (MLF), midbrain reticular nucleus (MRN), lateral thalamus (LatThal), medial thalamus 
(MedThal), hypothalamus (Hypothal), dentate gyrus of hippocampus (HDG), CA1 of 
hippocampus (HCA1), internal capsule (IntCap), cerebral cortex at level of thalamus (Cthal), 
septal nuclei (SepNuc), cerebral cortex at level of septal nuclei (Csep). 
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Abstract 
 
 The accumulation of misfolded prion particles in transmissible spongiform 
encephalopathies (TSEs) stimulates a neuroinflammatory response characterized by activation and 
proliferation of astrocytes and microglia.  Misfolded proteins in the healthy cell are degraded, in 
part, by the 26S ubiquitin proteasome system, whose dysfunction has been documented in prion 
infection.  As part of the neuroinflammatory response, human neurodegenerative “prionopathies”, 
such as Alzheimer’s disease, additionally upregulate the expression of inducible proteasome 
subunits, called immunoproteasomes.  The effect of immunoproteasome induction on the 
pathology of protein misfolding diseases is uncertain, and mixed clinical outcomes are associated 
with their inhibition.  This study used in-situ hybridization to characterize expression of PSMB10, 
an immunoproteasome subunit, over a timecourse of a murine model of scrapie infection, and 
correlate any changes to markers of prion-associated neuropathology, including spongiform 
change, PrPsc deposition, Iba1, GFAP, iNOS, and Arg1.  We successfully demonstrated PSMB10 
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expression in 16 brain regions, however no significant temporal upregulation of PSMB10 
transcription was observed, and there was no correlation to prion neuropathology.   
 
Introduction 
Transmissible spongiform encephalopathies are mediated by the toxic aggregation of 
misfolded analogs of cellular prion protein, PrPc.  PrPc is composed of a 208 amino acid chain that, 
after maturation in the golgi, is trafficked to the plasma membrane, where it becomes associated 
with the outer leaflet of lipid rafts (Castle et al., 2017).  While defunct PrPc undergoes recycling 
via constitutive endocytosis (Campana et al., 2005),  dysmature PrPc can be redirected into the 
cytosol, where it undergoes degradation by the 26S proteasome (Ma et al., 2001).  Inhibition of 
cellular proteolysis can not only accelerate aggregation of misfolded PrP conformers (PrPsc), but 
can furthermore trigger the cell’s endoplasmic reticulum stress response (Orsi et al., 2006).   This 
mechanism further promotes both misfolding (Orsi et al., 2006) and neuronal apoptosis 
(Kristiansen et al., 2005).  Moreover, misfolded oligomers of PrPsc, have been shown to inhibit the 
26S proteasome directly, potentially by stabilizing the proteolytic barrel in the closed position 
(Kristiansen et al., 2007).   
Antigen-presenting and non-immune cells under stress can substitute an inducible subset 
of proteasomal subunits, β1i (LMP2, PSMB9), β2i (MECL1, PSMB10), β5i (LMP7, PSMB8), in 
place of constitutive 26S proteasomal subunits β1, β2 and β3, respectively.  The resulting 
immunoproteasome is capable of higher rates of proteolysis and displays an altered cleavage 
pattern that favors degradation of oxidized proteins and MHC class I presentation (Ferrington et 
al., 2012; Seifert et al., 2010).  Immunoproteasomes are expressed at low levels in healthy brains 
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(Stohwasser et al., 1997), and can be upregulated in microglia in response to IFNγ stimulation 
(Stohwasser et al., 2000).    
Immunoproteasome induction has been demonstrated in neurodegenerative diseases, such 
as Alzheimer’s(AD), Huntington’s (HD) and amyotrophic lateral sclerosis (ALS) (Gavilan et al., 
2009; Orre et al., 2013; Cheroni et al., 2009; Mishto et al., 2006; Diaz-Hernandez et al., 2003).  
Like prion diseases, these entities share a common element of toxic accumulation of self-
propagating misfolded proteinaceous particles.  Investigations into the role of immunoproteasomal 
induction in sterile neuroinflammatory disorders has yielded mixed, entity-specific results, with 
evidence for both protection and exacerbation of pathology (Orre et al., 2013; Wagner et al., 2017; 
X. Chen et al., 2015; Moritz et al., 2017; Ahtoniemi et al., 2007).   
Prion infection is known to stimulate a neuroinflammatory response, characterized by 
microglial and astrocytic hypertrophy and proliferation.  Recent transcriptomic studies suggest that 
prion infections are associated with a proinflammatory cytokine milieu (Vincenti et al., 2015; 
Carroll et al., 2016; Tribouillard-Tanvier et al., 2009; Newsom et al., 2011; Moody et al., 2011; 
Song et al., 2012). Despite the inflammatory nature of prion disease and evidence of expression in 
analogous neurodegenerative entities, investigations into prion-mediated immunoproteasomal 
induction are limited in the literature.  A single report by Amici et al. failed to demonstrate 
increased immunoproteasomal subunit expression in brainstem homogenates of scrapie-infected 
sheep (Amici et al., 2010). Spatiotemporal analyses of immunoproteasomal expression in prion 
disease have not been represented in the literature.  
In the current study, we used quantitative in situ hybridization to determine the 
temporospatial distribution of immunoproteasome subunit PSMB10 (MECL1, β2i) mRNA 
expression over the course of prion disease using a murine intracranial RML scrapie infection 
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model. We also correlated PSMB10 expression to glial activation, PrPsc deposition and 
vacuolation data generated from a parallel timecourse study. We found that, while PSMB10 
transcripts are present in healthy and diseased brain, there were no significant trends in expression 
over time and no correlation to of PSMB10 to RML scrapie neuropathology in this model.  
 
Materials and Methods 
Animals and tissue preparation 
This study used archived tissue blocks of murine brain from the previous study (Chapter 
2). Briefly, C57BL/6 mice, aged 6 to 8 weeks, were inoculated intracranially into the right cerebral 
hemisphere with 20 µL of 10% w/v brain homogenate in PBS pooled from C57BL/6 mice 
terminally ill with the mouse-adapted Rocky Mountain Laboratories (RML) strain of the scrapie 
agent. Groups of four mice were euthanized at predetermined time points of 30, 60, 90 and 120 
days post inoculation (DPI), along with a group of animals that were allowed to survive until 
clinical signs necessitated euthanasia at 155 DPI. Age-matched C57BL/6 negative control mice 
inoculated with 10% w/v normal C57BL/6 brain homogenate in PBS were also included at each 
time point. Brains were collected into 10% neutral buffered formalin. After 24 hours of fixation, 
brains were transversely sectioned at four levels: mid-cerebellum, rostral colliculus, thalamus and 
hypothalamus, and rostral cerebrum at level of septal nuclei. Tissues were processed by routine 
histologic methods, embedded in paraffin, sectioned at 5 μm, and mounted on glass slides for in-
situ hybridization.  For this study, we analyzed a subset of n=3 infected and n=1 control brains 
from animals sacrificed at 30, 60, 120, and 155DPI in the archived timecourse.  
 
 
94 
 
RNAscope in-situ hybridization 
RNAscope® (ACDbio), a proprietary in-situ hybridization platform, was used to visualize 
transcribed immunoproteasomal mRNA. We obtained a custom probe from ACDbio specific to 
the murine transcript of immunoproteasomal subunit PSMB10 (Cat#452541, NCBI Reference 
Sequence NM_013640.3, target region 120-1226). This probe was applied to deparaffinized tissue 
sections following the manufacturer’s protocol for the RNAscope® 2.5 HD Assay (RED) kit.  
Briefly, slides were baked for 1hr at 60C and deparaffinized through a xylene/alcohol series.  
Tissues were incubated with hydrogen peroxide for 10 minutes, washed and boiled in RNAscope® 
target retrieval solution for 15 minutes.  A protease solution was applied to tissues and incubated 
for 30min at 40C in the HybEz™ oven.  After washing in distilled water, tissues were incubated 
with the hybridization probe for 2 hours at 40C.  After removing unbound probe with RNAscope® 
wash buffer, signal was enhanced through a series of incubations with 6 amplification probes with 
intervening washes.  Incubation times and temperatures followed the manufacturer’s protocol, with 
exception of Amp 5, which was extended to 60 minutes.  Signal detection solution was applied to 
tissues for 10 minutes at room temperature.  After washing slides in distilled water, tissues were 
redirected into an immunohistochemistry procedure to label Iba1.  
 
Immunohistochemistry 
Washed slides from the completed RNAscope® protocol were blocked with 5% BSA for 
60 minutes, and incubated with rabbit anti-Iba1 antibody at a 1:250 dilution (019-19741, Wako) 
for 24 hours at 4C.  After washing with TBST, slides were incubated with goat-anti-rabbit IgG 
secondary HRP-conjugated polymer (ab2891, Abcam) for 30 minutes at room temperature, 
washed and developed with Vector Nova Red HRP substrate (SK-4800, Vector Laboratories), per 
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kit instructions. Slides were then counterstained with 50% Gill’s #2 hematoxylin and dried in a 
60C oven prior to coverslipping with Ecomount permanent mounting medium (EM897L, Biocare).  
 
Image Analysis 
The chromogenic probe in the RNAscope® 2.5HD Red kit can be visualized both in 
brightfield and under fluorescent excitation, a property that was exploited to enhance signal 
recognition in brightfield images.  Immunohistochemical labeling was captured using an Olympus 
DP73 camera mounted on an Olympus BX53 fluorescence microscope, operated with cellSens 
imaging software (Olympus, USA).  2400x1800 brightfield images were generated at 400x for all 
brain regions, except medial thalamus (20x).  ISH signal was captured at the same location as the 
brightfield image by switching to fluorescence excitation with an X-Cite 120LED illuminator 
(Lumen Dynamics Group) at a wavelength of 550nm (red fluorescent protein filter).  Select 
brightfield and fluorescent image pairs were superimposed in cellSens by using the 
Image>Combine Channels command. Captured fluorescence images were processed using the 
Area Quantification module v1.0 FL within the HALO image analysis platform (v2.0.1145.19, 
Indica Labs). Briefly, the red probe signal was selected as Dye 1. A base threshold intensity value 
was assigned to image sets and manually adjusted, as needed, for images with higher 
autofluorescence to accurately reflect probe distribution in the regions of interest.  Total probe 
signal was quantified in each region of interest as % Dye 1 Positive Tissue.  
 
Statistical analysis 
Data were analyzed using a generalized linear model to detect significant differences in 
quantified PSMB10 probe signal between mock-inoculated and RML-infected animal groups. 
96 
 
DPI, brain location and treatment condition were included as fixed effects in the model. Simple 
effect comparisons between the least squares (LS) means of mock-inoculated and infected animal 
groups were conducted at each DPI for each brain region to determine the degree of significance.  
Pearson correlation analysis was used to evaluate temporal associations between PSMB10 and 
previously presented immunoreactivity data for PrPsc, Iba1, GFAP, iNOS and Arg1. Results were 
considered statistically significant if p<0.05. The software for conducting statistical analysis was 
SAS version 9.4. 
No statistical significance was calculated for temporal trends in control animals due to 
inclusion of a single mock-inoculated animal per collection timepoint.  Evaluation of relative total 
PSMB10 expression between brain regions, probe distribution and cellular colocalization were 
based on qualitative visual assessment of trends in data and images 
 
Results 
PSMB10 transcript distribution  
The ISH signal was interpreted in both brightfield and fluorescence images as 1 transcript 
per punctate fluorescent dot (Figure 1).  PSMB10 expression was quantified as % area positive for 
probe (Figure 2). Signal puncta appeared reasonably evenly distributed through the brain regions 
on visual evaluation of acquired images, with exception of increased probe density in the granular 
layer of the dentate gyrus, pyramidal layer of CA1, and Purkinje layer of the cerebellum (Figure 
1). PSMB10 transcript levels were overall lower in white matter of cerebellar peduncles and the 
internal capsule, and were present at the highest level in the vestibular nuclei.  
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PSMB10 probe expression over time 
There was a temporal upregulation of PSMB10 expression in control animals, with age-
associated increases in the vestibular nuclei, cerebellar nuclei, colliculus and cortex at the level of 
the thalamus (Figure 2).  Because control groups only featured an n=1 for each location:timepoint 
combination, statistical significance could not be calculated through-pair-wise comparison of 
means.  PSMB10 expression in RML-infected mice did not change significantly over time 
compared to mock-inoculated controls.  Similarly, pair-wise comparisons of 60, 120 and 155 DPI 
animals to the 30 DPI infected group did not yield significant increases in PSBM10 expression.   
Pearson’s correlation coefficients were calculated to evaluate any temporal association 
between PSMB10 expression in control and infected animals over time (Table 1).  A strong 
positive linear relationship was only observed in the colliculus, indicating that the temporal 
increase in controls was likely reproduced in the infected animals only at this location.  
 
PSMB10 expression and microglia 
Microglial expression of PSMB10 was evaluated at 30 and 150DPI by dual microglial Iba1 
IHC and PSMB10 ISH.  PSMB10 does not exclusively colocalize with microglia (Figure 4).  
Although sporadic signal puncta overlie microglial processes (Fig. 4, insets), the vast majority of 
transcripts are found in unlabeled neuropil or in neuronal cytoplasm.  This distribution does not 
subjectively appear significantly different between early and late infection timepoints.  
 
Correlation analysis between PSMB10 expression and markers of prion neuropathology.  
 Prion disease is associated with spongiform change, deposition of PrPsc, microgliosis and 
astrocytosis.  These changes were recapitulated in a parallel infection timecourse using archived 
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tissues from this model.  Additionally, we have previously demonstrated induction of the glial 
polarization markers iNOS and Arg1 late in disease incubation.   Pearson’s correlation coefficients 
were calculated to evaluate association between PSMB10 expression and data documenting 
temporal trends in PrPsc, Iba1, GFAP, iNOS and Arg1 immunoreactivity over the infection 
timecourse at each of the 16 brain regions.  Stain pairs with r>.8 were considered to have a strong 
positive linear relationship.  Only pairs with a strong positive relationship were found to have a 
p<0.5. 
 Overall, due to lack of temporal changes in expression, PSMB10 exhibited minimal 
correlation to any markers of neuropathology.  No statistically significant associations were 
present between PSMB10, spongiform change, and gliosis.  Strong positive relationships were 
observed between PSMB10 and PrPsc and the internal capsule (p<.05) and septal nuclei (p<.001).  
PSMB10 and iNOS had positive relationships at the same locations (p<.05).   A statistically 
significant relationship between iNOS and Arg1 was only present in the colliculus (p<.01).  These 
few correlations are not compelling in impact, as the modest temporal trends for the two 
diencephalic structures did not achieve statistical significance on pairwise comparisons and the 
septal correlation was the consequence of a relative flat-line in values over time for all 3 stains.   
 
Discussion 
This timecourse attempted to characterize temporospatial changes in the expression of 
PSMB10, an immunoproteasome subunit, over the course of prion infection.  We successfully 
demonstrated expression of immunoproteasome subunit PSMB10 transcripts in all 16 brain 
regions over time in healthy C57Bl/6 control mice, but did not detect temporal trends suggestive 
of upregulation in infected animals.   
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Immunoproteasomes are present at low levels in healthy human and murine neural tissues 
(Stohwasser et al., 1997; Boegel et al., 2018), and expression is upregulated in ageing and inflamed 
brains (Mishto et al., 2006). Cellular colocalization varies by stimulus.  Mice infected with 
lymphocytic choriomeningitis virus, an established model of sterile neuroinflammation (Kang et 
al., 2008), demonstrate increased expression of PSMB10 and LMP2 in microglial processes and 
astrocytic nuclei (Kremer et al., 2010).  Little to no immunoproteasomal induction was observed 
in neurons or astrocytic cytoplasm in this infection model (Kremer et al., 2010). Upregulation of 
LMP2 and LMP7 has been demonstrated in neurons, astrocytes and plaque-associated amoeboid 
microglia in Alzheimer’s disease (Mishto et al., 2006; Orre et al., 2013), and neurons of 
Huntington’s disease (Diaz-Hernandez et al., 2003).  Increased immunoproteasome expression has 
been reported in reactive glia in ALS (Puttaparthi et al., 2005; Ahtoniemi et al., 2007; Cheroni et 
al., 2009), and was recently documented in neurons, astrocytes and microglia of a PD model (Ugras 
et al., 2018).  Thus, immunosubunit upregulation has been documented in multiple 
neurodegenerative protein misfolding disorders.   
In this timecourse, PSMB10 transcription was documented in all 16 analyzed brain regions 
of both control and infected animals.  White matter tracts of the cerebellar peduncles and the 
internal capsule had the lowest level of quantified PSMB10 signal.  The highest signal density 
relative to other brain regions was observed in the vestibular nuclei. Signal puncta were associated 
with Iba1-positive microglial processes, neuronal cytoplasm and unlabeled neuropil throughout 
the brain in both 30 and 150DPI animals, and no overt differences in cell association were observed 
between early and late disease. There were increased numbers of signal puncta in areas of high 
neuronal density, such as the granular layer of the dentate gyrus, pyramidal layer of CA1, and 
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Purkinje layer of the cerebellum.  However, these locations were not overall associated with 
increased PSMB10 expression relative to other brain regions.   
Immunoproteasome subunit incorporation is stimulated by inflammatory cytokines 
including TFNα and IFNγ (Ferrington et al., 2012), and upregulation in response to NO has been 
demonstrated in vascular endothelium (Kotamraju et al., 2006).  Both TNFα (Vincenti et al., 2015; 
Carroll et al., 2016) and IFNγ (Tribouillard-Tanvier et al., 2009; Newsom et al., 2011) secretion 
has been demonstrated in response to prion infection in the brain, and we have previously 
documented increased iNOS expression in the late stages of scrapie incubation in this model.  
Thus, upregulation of PSMB10 was anticipated in our model. However, quantification of PSMB10 
expression over time across all brain regions failed to demonstrate temporal upregulation of this 
subunit in infected animals.   Additionally there was no visually apparent increase in colocalization 
of PSMB10 with Iba1-positive microglia over time, and no significant temporal correlation with 
data quantifying Iba1, GFAP, iNOS or Arg1 immunoreactivity in a parallel timecourse of this 
infection model.  These results suggest that microglia do not upregulate PSMB10 transcription in 
response to prion infection.  Although unexpected, our findings corroborate Amici et al’s 2010 
report describing an absence of increased immunoproteasome subunit induction in the brainstem 
of scrapie-infected sheep.   
Immunoproteasome expression is reported to increase in the ageing brain (Mishto et al., 
2006; Gavilan et al., 2009).  In mice, upregulation of immunosubunits was reported at 15-18 
months of age, compared to animals aged 3-6 months (Orre et al., 2013).  Although our animals 
did not exceed ~211 days of age (7.5 months) at the final timepoint, we observed apparent temporal 
increases in PSMB10 expression in control animals in several locations including the vestibular 
nuclei, cerebellar nuclei, colliculus, and cortex at the level of the thalamus.  If there was truly no 
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effect of prion infection on immunoproteasome expression in infected brains, we would anticipate 
a similar temporal trend at these locations and a strong positive linear relationship between mock 
and RML-inoculated animals.  Interestingly, correlation analysis between temporal expression in 
control and infected brains at each of these location revealed a strong positive relationship only in 
the colliculus (p<.05).   No complementary ageing trends were observed at the other 3 locations 
exhibiting significant temporal upregulation in control mice. Combined, these findings suggest 
that normal age-associated upregulation of PSMB10 expression in some areas of the brain may be 
disrupted in infected animals, however higher numbers of control replicates would be necessary 
to substantiate this claim. 
Thus, no strong evidence of prion-associated temporal PSBM10 transcriptional 
upregulation was demonstrated in our infection model.  Several explanations for these findings 
were considered, including shifts in microglial immunophenotypes over time, asymmetric subunit 
incorporation, and the limitation of transcript quantification as a measurement of subunit 
induction.   
Unlike proinflammatory M1 macrophages, M2, or “alternatively activated”, monocytes do 
not appear to upregulate immunoproteasome subunit mRNA transcription in response to 
experimental polarization (S. Chen et al., 2016).   M2 microglia have been reported to cluster 
around amyloid plaques in Alzheimer’s disease (Jimenez et al., 2008), thus we questioned whether 
a potential shift in microglial immunophenotype could be responsible for the lack of PSMB10 
upregulation. However, previous work by our laboratory did not detect a significant Arg1-positive 
microglial population indicative of M2 phenotype predominance, thus alternative polarization 
does not account for the lack of PSMB10 induction in this model.   
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Synthesis of mixed proteasomes containing both constituent and inducible subunits is 
possible (Kaur et al., 2016).  Studies of immunoproteasome expression in neurodegenerative 
disease frequently report increases in LMP2 (PSMB8) and LMP7 (PSMB9) (Cheroni et al., 2009; 
Diaz-Hernandez et al., 2003; Puttaparthi et al., 2005), but MECL1 (PSMB10) upregulation is 
inconsistent (Diaz-Hernandez et al., 2003; Cheroni et al., 2009; Orre et al., 2013).  Our preliminary 
studies demonstrated relatively more PSMB10 expression in control brains, leading to the selection 
of this probe for evaluation in infected tissues.  PSMB8 and PSMB9 quantification may have 
yielded different expression patterns and should be explored in the future.   
Finally, it is important to consider the limitations of evaluating only transcriptional 
fluctuations as a measure of protein upregulation.  Transcript levels are estimated to predict only 
approximately 40% of the change in cellular protein levels, with the rest likely accounted for by 
post-transcriptional regulatory mechanisms (Vogel et al.).  This discrepancy has been 
demonstrated in studies of immunoproteasome expression. Chen et al. noted that macrophages 
polarized towards an M2 phenotype in-vitro show an upregulation of LMP2 and LMP7 protein 
levels by Western blot analysis, with no corresponding changes in mRNA transcript levels (S. 
Chen et al., 2016).  Similarly, Orre et al. found no difference in murine PSMB10 (MECL-1) 
plaque-adjacent transcript levels in a model of AD, but demonstrated an increase in 
immunoreactivity against the translated protein in the same regions (Orre et al., 2013). 
Additionally, proteolytic activity of all three subunits was increased in diseased areas of both 
murine and human brain samples (Orre et al., 2013).  Thus, post-translational regulation of protein 
expression has been documented both in experimental monocyte polarization and in vivo.  We 
were unable to achieve satisfactory immunoreactivity against subunits when conducting 
preliminary IHC experiments, thus ISH was selected as the best method for in-situ evaluation of 
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subunit expression.  However, our lack of transcriptional PSMB10 induction may not reflect 
subunit protein levels or activity.   
In summary, while we did not observe temporal upregulation of PSMB10 mRNA in 
evaluated regions of infected brains, we successfully demonstrated relative expression across 16 
brain regions and provided evidence for potential disruption of age-related immunoproteasomal 
upregulation.  The results of this study highlight the need for protein-level and, potentially, 
functional analysis of immunoproteasome expression in prion disease.  Thus, we believe that future 
investigation into immunoproteasome involvement in prion infection would benefit from in-situ 
evaluation of protein expression for all three subunits with correlation to local cytokine milieus 
and cellular colocalization of target expression.   
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Figures and Figure Legends 
 
 
 
Figure 1. PSMB10 mRNA expression in brain. Red puncta each correspond to a hybridized 
transcript copy.   Increased PSMB10 probe density is observed in the Purkinje layer of the 
cerebrum (1a,d), granular layer of the dentate gyrus (1b,e) and pyramidal layer of CA1 (1c,f). In-
situ hybridization, RNAscope, 400x, brightfield hematoxylin counterstain (a-c), RFP fluorescence 
(d-e).   
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Figure 2.  Total PSMB10 hybridization probe signal in 16 brain regions over RML infection 
timecourse.  PSMB10 expression quantified as % tissue positive for red hybridization signal.  Bars 
represent mean±SE values for mock-inoculated and RML-inoculated animal cohorts at each 
timepoint.  *p < 0.05; significant differences compared with control (mock-inoculated) animals. 
Horizontal lines represent mean % tissue positive for PSMB10 for all mock-inoculated (blue) and 
all RML-inoculated animals (red). Vestibular nuclei (VestNuc), cerebellar peduncles (CerPed), 
cerebellar cortex (nodulus X, NodX), cerebellar nuclei (CerNuc), colliculus (Coll), medial 
longitudinal fasciculus (MLF), midbrain reticular nucleus (MRN), lateral thalamus (LatThal), 
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medial thalamus (MedThal), hypothalamus (Hypothal), dentate gyrus of hippocampus (HDG), 
CA1 of hippocampus (HCA1), internal capsule (IntCap), cerebral cortex at level of thalamus 
(Cthal), septal nuclei (SepNuc), cerebral cortex at level of septal nuclei (Csep).  
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Figure 3. Immunoreactivity for Iba1 with concurrent ISH for PSMB10 in a 30DPI animal (4a) and 
a 155DPI animal (4b). Sporadic signal puncta overlie microglial processes (insets). While 
hypertrophy of microglial processes is visible in the clinical animal, the majority of PSMB10 
signal is present in the neuropil and around neurons, as in the 30DPI animal. Brainstem (4a), 
cerebellar peduncle (4b), NovaRed, hematoxylin and RNAscope® 2.5 HD Assay (RED), 400x.  
 
 
  
111 
 
 
 
 
 
 
 
 
 
 
 
Table 1.  Pearson’s correlation coefficients (r=) for PSMB10 expression in control and infected 
animals at each timepoint.   Vestibular nuclei (VestNuc), cerebellar peduncles (CerPed), cerebellar 
nuclei (CerNuc), colliculus (Coll), medial longitudinal fasciculus (MLF), midbrain reticular 
nucleus (MRN), lateral thalamus (LatThal), medial thalamus (MedThal), hypothalamus 
(Hypothal), dentate gyrus of hippocampus (HDG), CA1 of hippocampus (HCA1), internal capsule 
(IntCap), cerebral cortex at level of thalamus (Cthal), septal nuclei (SepNuc), cerebral cortex at 
level of septal nuclei (Csep). No correlation for cerebellar cortex (nodulus X, NodX) due to lack 
of control data.  
 
  
Psmb10 Control 
vs Infected p< 
VestNuc -0.01482 0.9852 
CerPed 0.9741 0.0259 
CerNuc 0.34767 0.6523 
Coll 0.97664 0.0234 
MLF 0.54168 0.4583 
DMN 0.69238 0.3076 
Thal40 0.51597 0.484 
MidThal20 0.58637 0.4136 
Hypothal 0.66056 0.3394 
HDG -0.23401 0.766 
HCA1 -0.95709 0.1872 
IntCap -0.83077 0.1692 
Cthal 0.17133 0.8287 
SepNuc -0.25761 0.8341 
Csep -0.33099 0.669 
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Psmb10 vs Iba1  GFAP  iNOS  Arg1  SE  PrPSc 
VestNuc -0.53557 -0.40831 0.20596 -0.75826 -0.50467 -0.42187 
CerPed 0.79655 0.8695 0.8132 0.55975 0.79405 0.81339 
NodX -0.98576 0.69452 0.76046 -0.52515 -0.98767 -0.98642 
CerNuc 0.26602 0.26602 0.10939 0.74259 -0.19863 0.08393 
Coll 0.76548 0.90606 0.60003 0.97937 0.84591 0.90154 
MLF 0.76711 0.79617 0.76569 0.91792 0.56688 0.33841 
DMN 0.10864 -0.00047 0.2846 0.84962 0.01254 -0.19432 
Thal40 0.49641 0.44046 0.60527 0.74423 0.50055 0.33999 
MidThal20 0.25275 0.26954 0.62234 0.59456 0.30173 0.68392 
Hypothal 0.60024 0.12179 -0.70631 0.28087 0.70624 0.34422 
HDG 0.74322 0.94445 0.90707 0.54555 0.72098 0.91649 
HCA1 0.52872 0.52343 0.55918 0.1969 0.46349 0.5274 
IntCap 0.90278 0.56756 0.96973 0.26543 0.89091 0.96057 
Cthal 0.73643 0.30371 0.34285 0.74526 0.43603 0.65924 
SepNuc 0.80855 -0.90864 0.99936 0.36854 0.83045 0.99994 
Csep -0.8197 -0.71302 0.8507 -0.84917 -0.84917 -0.49881 
Significance (p value)       
p<0.05 p<0.001      
 
Table 2.  Pearson’s correlation coefficients (r=) comparing PSMB10 expression with IHC stains 
from neuroinflammatory timecourse at each timepoint.   Vestibular nuclei (VestNuc), cerebellar 
peduncles (CerPed), cerebellar nuclei (CerNuc), colliculus (Coll), medial longitudinal fasciculus 
(MLF), midbrain reticular nucleus (MRN), lateral thalamus (LatThal), medial thalamus 
(MedThal), hypothalamus (Hypothal), dentate gyrus of hippocampus (HDG), CA1 of 
hippocampus (HCA1), internal capsule (IntCap), cerebral cortex at level of thalamus (Cthal), 
septal nuclei (SepNuc), cerebral cortex at level of septal nuclei (Csep). No correlation for 
cerebellar cortex (nodulus X, NodX) due to lack of control data. 
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CHAPTER 4. GENERAL CONCLUSIONS 
 
Summary 
 Transmissible spongiform encephalopathies and human neurodegenerative protein 
misfolding diseases exhibit parallels in the molecular identity, mechanism of propagation and 
neuroinflammatory response to their respective causative agents.  Both deleterious and 
neuroprotective functions have been attributed to activated glial cells.  Microglia and astrocytes 
are heterogeneously distributed throughout the brain, with regional variations in density and 
physiology.  Different glial reactive phenotypes have been described in neurodegenerative 
diseases.  An additional feature of neuroinflammation and accumulation of misfolded cellular 
proteins in these entities is variable impairment of proteolysis and induction of 
immunoproteasomes, a functional subtype of the ubiquitin proteasome system.  Prion diseases 
exhibit strain-specific lesion distribution patterns, and the immunophenotypes of reacting glia have 
not been resolved throughout the brain.  The goal of this dissertation was to characterize the 
temporospatial glial response to prion infection and to evaluate tissues for disease-associated 
changes in immunoproteasome expression.  We found that microglia and astrocytes express 
different activation markers in late disease incubation, and that closely apposed anatomic locations 
can display variable patterns of neuropathology.  We also demonstrated variation in expression of 
immunoproteasome subunit PSMB10 throughout the brain.  This work lays a foundation for 
resolving glial immunophenotypes in prion infection and underscores the value of in-situ analysis 
of protein expression.   
 Chapter 2 presented a comprehensive spatiotemporal investigation of neuropathology 
associated with intracranial infection with RML scrapie.  We characterized vacuolation, PrPsc 
deposition and glial activation in 15 locations across the murine brain, and we utilized quantitative 
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immunohistochemistry to evaluate the expression of iNOS and Arg1, canonical markers of glial 
activation, and demonstrated upregulation of both in late disease incubation.  Our findings support 
the existence of a primarily proinflammatory microglial profile, characterized by upregulation of 
iNOS, with negligible Arg1 expression.  Astrocytes, however, were found to upregulate iNOS 
primarily in two white matter tracts, but display either transient or sustained increases in Arg1 
expression in multiple brain regions.  These results suggest that astrocytes may assume variable 
location-dependent activation phenotypes, and, to our knowledge, constitute the first such report 
in experimental prion infection.   
 In chapter 3, we used RNAscope®, an in-situ hybridization platform, to analyze expression 
of PSMB10 transcripts across a parallel timecourse of the same RML infection model described 
in chapter 2.  PSMB10 encodes MECL1/β2i, the second subunit incorporated in 
immunoproteasome assembly.  We demonstrated heterogeneous transcription levels across the 
healthy murine brain, but did not detect changes in transcript numbers in infected animals over 
time.  To date, this represents the first comprehensive anatomically resolved characterization of 
PSMB10 expression in the healthy murine brain.  Additionally, we detected potential temporal 
increases in PSMB10 at several locations in control animals that were not reproduced in infected 
animals.  Age-related upregulation of immunoproteasome subunits has been demonstrated in 
murine and human brains, and our findings may provide evidence towards disruption of normal 
expression in prion disease.   
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Recommendations for Future Research 
Expanding the marker pool: A(n even more) comprehensive analysis  of the 
neuroinflammatory response to prion infection 
Our findings demonstrate the utility of in-situ analysis of marker expression on a 
subanatomic scale.  Whole or even partially dissected brain homogenates frequently used in 
cytokine and transcriptomic analysis in prion research are unlikely to have detected the nuanced 
expression of glial activation markers we described in anatomically apposed locations.  
However, our study accommodated evaluation of only two glial activation markers, which 
carries the risk of grossly underrepresenting glial heterogeneity and oversimplifying phenotype 
complexity (Ransohoff, 2016b).  Additionally, the limited insight yielded by the PSMB10 ISH 
timecourse underscored the need for complementary protein-level analysis.  Contextualization of 
these findings would furthermore have benefited from concurrent evaluation of the local 
cytokine milieu.   
Ideally, these shortcomings would be resolved with the use of a comprehensive in-situ 
proteomics modality.  However, multiplex analysis, especially that targeting protein expression, 
is limited either by availability of effective antibodies, such as with immunohistochemistry, or by 
the lack of microanatomic specificity, such as with Western blotting, which necessitates use of 
tissue homogenates. Laser dissection microscopy and subsequent proteomic and transcriptomic 
analysis of select cells is an option, however this modality does not easily support mass-
throughput, as would be desired for a comprehensive anatomic timecourse.  
We believe that the above requirements can be satisfied by MALDI imaging mass-
spectrometry (IMS), a platform used for direct proteomic analysis of even paraffin-fixed 
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formalin-embedded tissues, with demonstrated applications in cancer classification, 
pharmacokinetics, and neurodegenerative disease research (Norris et al., 2013).  Using this 
technique to analyze infection timecourses would yield the most relevant and comprehensive 
profile of the neuroinflammatory response to prion infection due to IMS’s capacity to resolve in-
situ protein expression down to a subcellular level.  Furthermore, this modality is label-free and 
tissue-sparing, and can thus not only provide an expression profile for an unlimited number of 
protein targets across a tissue section, but leaves the sample essentially unaltered and available 
for redirection towards subsequent counterstaining or immunohistochemical analysis (Norris et 
al., 2013).  Thus, we would propose to use IMS on the remaining archived tissues from this 
timecourse to generate the first truly exhaustive temporospatial profile of neuroinflammatory 
marker and proteasome subunit expression  
 
Functional contribution of immunoproteasomes to prion pathology 
Constitutive proteasome inhibition has been documented in prion disease.  Even 
successful demonstration of immunoproteasome transcript or protein expression fluxes in prion-
infected tissues would not address the functionality of these proteasomes. Additional insight into 
any potential role of immunoproteasomes in the pathophysiology of prion infection may be 
gained from timecourse studies using immunoproteasome inhibitors.  Subunit-specific and pan-
immunoproteasomal inhibitors are commercially available, and some are actively used in cancer 
therapeutics (Miller et al., 2013).  Immunoproteasome inhibition in other neurodegenerative 
protein misfolding diseases has yielded mixed clinical outcomes (Orre et al., 2013; Wagner et al., 
2017; Moritz et al., 2017; Ahtoniemi et al., 2007),  but no similar study has been undertaken in 
prion research.  We believe assessment of disease progression in the absence of functional 
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immunosubunits would complement expression analysis and supply valuable mechanistic 
insight.   
Concluding remarks 
Neuroinflammation has been proposed as a therapeutic target for protein misfolding 
diseases (Ransohoff, 2016a; Venigalla et al., 2016; Rizzo et al., 2014).  Modulation of glial 
activation and population ablation in prion disease has been investigated, but yielded mixed 
clinical outcomes (Gomez-Nicola et al., 2013; Carroll et al., 2018; Zhu et al., 2016).  
Understanding glial dynamics in prion disease may identify targets for a more nuanced 
therapeutic approach.  Our findings establish a baseline glial activation profile in prion infection, 
characterized by a proinflammatory microglial population, and a mixed spatially segregated 
astrocytic profile.  Additionally, this work represents the first known characterization of 
PSMB10 expression across the murine brain, demonstrates the advantage of in-situ subanatomic 
marker expression analysis, and establishes the application of sequential chromogenic 
immunohistochemistry and RNAscope® in-situ hybridization in prion disease research.  
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APPENDIX. ADDITIONAL MATERIAL 
 
Table A1. Pearson’s correlation matrices comparing temporal trends in markers of prion-associated 
neuropathology in RML-infected animals at each brain location.   Pearson’s correlation coefficients (r=) 
are given in the table, and cell fill indicates significance (p<).   Spongiform change (SE), Iba1, GFAP, 
iNOS, Arg1, colocalization of Arg1 with microglia (Arg1Iba1) and astrocytes (Arg1GFAP), 
colocalization of iNOS with microglia (iNOSIba1) and astrocytes (iNOSGFAP).  Vestibular nuclei 
(VestNuc), cerebellar peduncles (CerPed), cerebellar nuclei (CerNuc), superior colliculus (Coll), medial 
longitudinal fasciculus (MLF), midbrain reticular nucleus (MRN), lateral thalamus (LatThal), medial 
thalamus (MedThal), hypothalamus (Hypothal), dentate gyrus of hippocampus (HDG), CA1 of 
hippocampus (HCA1), internal capsule (IntCap), cerebral cortex at level of thalamus (Cthal), septal nuclei 
(SepNuc), cerebral cortex at level of septal nuclei (Csep). 
 
 
 
 
 
  
Arg1Iba1 Arg1GFAP iNOSIba1 iNOSGFAP
VestNuc 0.95102 0.9687 0.99329 0.60063 0.89089 0.9217 0.85765 0.92898 0.86427
CerPed 0.99289 0.98286 0.72204 0.87809 0.95183 0.98246 0.96901 0.93922 0.86939
CerNuc 0.76251 0.96144 0.89117 0.6347 0.38764 0.76544 0.78245 0.60424 0.6078
Coll 0.83169 0.98986 0.98685 0.79645 0.94204 0.99023 0.99559 0.98684 0.98676
MLF 0.14466 0.68477 0.71233 0.91989 0.69583 -0.41257 0.18532 0.90383 0.78505
MRN 0.70148 0.85874 0.93035 0.861 0.42151 0.73515 0.9962 0.8155 0.97877
LatThal 0.89402 0.94254 0.88397 0.86634 0.88772 0.82928 0.7676 0.72197 0.98494
MedThal 0.66681 0.97971 0.85807 0.80222 0.87959 0.91647 0.756 0.62358 0.97608
Hypothal 0.24941 0.03675 0.68806 0.21469 0.63795 0.39081 0.2854 0.91013 -0.09183
HDG 0.93475 0.99007 0.61769 0.94542 0.97036 0.99955 0.61023 0.84676 0.68766
HCA1 0.81294 0.91468 0.77942 0.75589 0.69747 0.70287 0.55541 0.7008 0.93659
IntCap 0.89348 0.99787 0.21764 0.87661 0.67591 0.8999 0.45047 0.91565 0.84467
Cthal 0.88128 0.91107 0.95883 0.93327 0.81035 0.89017 0.94464 0.86406 0.61335
SepNuc 0.8983 0.54976 -0.35007 0.6715 0.79872 0.6462 0.58642 0.79346 -0.28948
Csep 0.82592 0.98096 0.87914 0.02897 0.51381 0.04116 0.40056 0.55758 0.38723
p<0.05 p<0.01 p<0.001
Arg1SE vs PrPsc Iba1 GFAP iNOS 
Significance (p value)
Arg1Iba1 Arg1GFAP iNOSIba1 iNOSGFAP
VestNuc 0.92855 0.96128 0.41249 0.9043 0.94736 0.69927 0.89547 0.72527 0.95102
CerPed 0.99718 0.7454 0.92383 0.93076 0.96394 0.95489 0.96346 0.89016 0.99289
CerNuc 0.83353 0.83353 0.54777 0.31421 0.77002 0.77497 0.72626 0.61416 0.76251
Coll 0.78308 0.89989 0.52856 0.89711 0.88983 0.878 0.74666 0.75747 0.83169
MLF 0.56933 0.66157 0.44172 0.56624 0.31681 0.73599 0.35995 0.52834 0.14466
MRN 0.82632 0.85741 0.71602 0.29355 0.65386 0.71179 0.7248 0.74426 0.70148
LatThal 0.96813 0.98781 0.78553 0.78566 0.71108 0.69575 0.67845 0.87463 0.89402
MedThal 0.73704 0.75761 0.84704 0.84762 0.64055 0.09973 0.902 0.64572 0.66681
Hypothal 0.73972 0.45849 -0.23577 0.40893 0.89672 0.71196 0.16935 0.41624 0.24941
HDG 0.92793 0.79613 0.99864 0.8249 0.93626 0.29027 0.60963 0.78108 0.93475
HCA1 0.97739 0.94425 0.99463 0.1741 0.21099 -0.02347 0.97623 0.94717 0.81294
IntCap 0.91738 0.61184 0.99655 0.28053 0.61783 0.00603 0.99859 0.99452 0.89348
Cthal 0.91988 0.8884 0.88725 0.9862 0.994 0.98676 0.72152 0.69435 0.88128
SepNuc 0.38372 -0.377 0.59343 0.5447 0.35822 0.28282 0.87477 -0.39301 0.8983
Csep 0.75843 0.94639 0.03782 0.82592 0.02412 0.38624 0.13615 0.08239 0.82592
p<0.05 p<0.01 p<0.001
PrPsc vs Iba1 GFAP iNOS SE
Significance (p value)
Arg1
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GFAP iNOS Arg1 Arg1Iba1 Arg1GFAP PrPSc SE
VestNuc 0.94843 0.53023 0.87471 0.94862 0.90695 0.92855 0.9687
CerPed 0.73941 0.94374 0.92414 0.95316 0.95107 0.99718 0.98286
CerNuc 0.97236 0.68619 0.51073 0.8861 0.90184 0.83353 0.96144
Coll 0.95901 0.86228 0.88528 0.96275 0.9763 0.78308 0.98986
MLF 0.96511 0.85249 0.81233 0.31857 0.83037 0.56933 0.68477
MRN 0.98022 0.71423 0.41149 0.6968 0.87141 0.82632 0.85874
LatThal 0.95565 0.90935 0.91512 0.86357 0.61372 0.96813 0.94254
MedThal 0.89728 0.83103 0.8924 0.93792 0.72737 0.73704 0.97971
Hypothal -0.18966 -0.46112 -0.24958 0.42165 0.96399 0.73972 0.03675
HDG 0.67889 0.94334 0.96674 0.99364 0.60951 0.92793 0.99007
HCA1 0.94233 0.95411 0.37692 0.4093 0.1879 0.97739 0.91468
IntCap 0.2794 0.89979 0.63768 0.8782 0.39975 0.91738 0.99787
Cthal 0.86599 0.77921 0.89084 0.92847 0.9499 0.91988 0.91107
SepNuc 0.5687 0.7314 0.79151 0.92599 0.66837 0.38372 0.54976
Csep 0.77985 0.16569 0.347 -0.10103 0.246 0.75843 0.98096
p<0.05 p<0.01 p<0.001
Iba1vs
Significance (p value)
Arg1 Arg1Iba1 Arg1GFAP PrPSc SE
VestNuc 0.62736 0.85899 0.89589 0.80528 0.96128 0.99329 0.94843
CerPed 0.82935 0.49597 0.58731 0.56173 0.7454 0.72204 0.73941
CerNuc 0.75119 0.68156 0.96411 0.97669 0.83353 0.89117 0.97236
Coll 0.7094 0.97607 0.99888 0.99734 0.89989 0.98685 0.95901
MLF 0.91221 0.91243 0.17227 0.77644 0.66157 0.71233 0.96511
MRN 0.78845 0.38647 0.71845 0.93475 0.85741 0.93035 0.98022
LatThal 0.74879 0.78132 0.69563 0.70409 0.98781 0.88397 0.95565
MedThal 0.61412 0.70118 0.69418 0.65733 0.75761 0.85807 0.89728
Hypothal 0.41895 0.9617 0.82073 0.04014 0.45849 0.68806 -0.18966
HDG 0.80261 0.4727 0.63197 -0.07538 0.79613 0.61769 0.67889
HCA1 0.94285 0.25572 0.32575 0.04889 0.94425 0.77942 0.94233
IntCap 0.60927 -0.47529 -0.1555 -0.70175 0.61184 0.21764 0.2794
Cthal 0.91302 0.80055 0.86618 0.93865 0.8884 0.95883 0.86599
SepNuc -0.26416 0.12113 0.37441 0.19911 -0.377 -0.35007 0.5687
Csep -0.19263 0.76389 0.26233 0.61427 0.94639 0.87914 0.77985
p<0.05 p<0.01 p<0.001
GFAP vs iNOS Iba1 
Significance (p value)
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PrPsc
VestNuc 0.19065 0.53023 0.62736 0.60063 0.41249
CerPed 0.76606 0.94374 0.82935 0.87809 0.92383
CerNuc 0.83074 0.68619 0.75119 0.6347 0.54777
Coll 0.57222 0.86228 0.7094 0.79645 0.52856
MLF 0.91266 0.85249 0.91221 0.91989 0.44172
MRN 0.74122 0.71423 0.78845 0.861 0.71602
LatThal 0.97732 0.90935 0.74879 0.86634 0.78553
MedThal 0.98803 0.83103 0.61412 0.80222 0.84704
Hypothal 0.21277 -0.46112 0.41895 0.21469 -0.23577
HDG 0.84382 0.94334 0.80261 0.94542 0.99864
HCA1 0.09532 0.95411 0.94285 0.75589 0.99463
IntCap 0.23838 0.89979 0.60927 0.87661 0.99655
Cthal 0.83529 0.77921 0.91302 0.93327 0.88725
SepNuc 0.38859 0.7314 -0.26416 0.6715 0.59343
Csep -0.75923 0.16569 -0.19263 0.02897 0.03782
p<0.05 p<0.01 p<0.001
GFAP SEiNOS vs Arg1 Iba1
Significance (p value)
Iba1 GFAP
VestNuc 0.87471 0.85899 0.19065 0.89089 0.9043
CerPed 0.92414 0.49597 0.76606 0.95183 0.93076
CerNuc 0.51073 0.68156 0.83074 0.38764 0.31421
Coll 0.88528 0.97607 0.57222 0.94204 0.89711
MLF 0.81233 0.91243 0.91266 0.69583 0.56624
MRN 0.41149 0.38647 0.74122 0.42151 0.29355
LatThal 0.91512 0.78132 0.97732 0.88772 0.78566
MedThal 0.8924 0.70118 0.98803 0.87959 0.84762
Hypothal -0.24958 0.9617 0.21277 0.63795 0.40893
HDG 0.96674 0.4727 0.84382 0.97036 0.8249
HCA1 0.37692 0.25572 0.09532 0.69747 0.1741
IntCap 0.63768 -0.47529 0.23838 0.67591 0.28053
Cthal 0.89084 0.80055 0.83529 0.81035 0.9862
SepNuc 0.79151 0.12113 0.38859 0.79872 0.5447
Csep 0.56217 0.76389 -0.75923 0.51381 0.82592
p<0.05 p<0.01 p<0.001
Significance (p value)
Arg1 vs iNOS SE PrPsc
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iNOSIba1 vs
VestNuc 0.8137 0.95501 0.76811
CerPed 0.96246 0.87791 0.86184
CerNuc 0.7758 0.89191 0.97349
Coll 0.98242 0.95308 0.96322
MLF 0.80295 0.87424 -0.29332
MRN 0.69919 0.7636 0.9706
LatThal 0.82514 0.6517 0.97384
MedThal 0.6598 0.50413 0.70137
Hypothal 0.13203 0.57164 0.31822
HDG 0.81642 0.13706 0.84037
HCA1 0.92378 0.93923 0.09745
IntCap 0.93695 0.57344 0.65833
Cthal 0.71526 0.71589 0.7764
SepNuc 0.377 -0.62453 0.23815
Csep 0.6767 0.14655 -0.12613
p<0.05 p<0.01 p<0.001
Iba1NIG GFAPNIG Arg1Iba1coloc
Significance (p value)
iNOSGFAP vs
VestNuc 0.81385 0.87755 0.81115
CerPed 0.8793 0.93562 0.72522
CerNuc 0.71892 0.81991 0.89534
Coll 0.99786 0.94895 0.96916
MLF 0.91678 0.96881 0.6184
MRN 0.82327 0.90445 0.98656
LatThal 0.89332 0.86393 0.86406
MedThal 0.98981 0.8438 0.78594
Hypothal -0.17343 0.65745 -0.27331
HDG 0.61262 0.37014 0.07653
HCA1 0.99116 0.94627 0.2801
IntCap 0.87285 0.67104 -0.0954
Cthal 0.42649 0.75756 0.67569
SepNuc 0.64 0.96637 0.21988
Csep 0.55152 -0.03847 -0.62397
p<0.05 p<0.01 p<0.001
Significance (p value)
Iba1NIG GFAPNIG Arg1GFAPcoloc
